



Published in final edited form as:

Dev Neurobiol. 2011 November ; 71(11): 982–1005. doi:10.1002/dneu.20953.

Role of Extracellular Matrix Proteins and Their Receptors in the Development of the Vertebrate Neuromuscular Junction

Neha Singhal and Paul T. Martin*

Abstract

The vertebrate neuromuscular junction remains the best-studied model for understanding the mechanisms involved in synaptogenesis, due to its relatively large size, its simplicity of patterning and its unparalleled experimental accessibility. During neuromuscular development, each skeletal myofiber secretes and deposits around its extracellular surface an assemblage of extracellular matrix (ECM) proteins that ultimately form a basal lamina. This is also the case at the neuromuscular junction, where the motor nerve contributes additional factors. Before most of the current molecular components were known, it was clear that the synaptic ECM of adult skeletal muscles was unique in composition and contained factors sufficient to induce the differentiation of both pre- and postsynaptic membranes. Biochemical, genetic and microscopy studies have confirmed that agrin, laminin (221, 421, and 521), collagen IV ($\alpha 3$ - $\alpha 6$), collagen XIII, perlecan and the ColQ-bound form of acetylcholinesterase are all synaptic ECM proteins with important roles in neuromuscular development. The roles of their many potential receptors and/or binding proteins has been more difficult to assess at the genetic level due to the complexity of membrane interactions with these large proteins, but roles for MuSK-LRP4 in agrin signaling and for integrins, dystroglycan, and voltage-gated calcium channels in laminin-dependent phenotypes have been identified. Synaptic extracellular matrix proteins and their receptors are involved in almost all aspects of synaptic development, including synaptic initiation, topography, ultrastructure, maturation, stability and transmission.

INTRODUCTION

Our understanding of the roles for extracellular matrix (ECM) proteins in the formation of the neuromuscular synapse began, in large part, with the approach of assessing motor axon or muscle regeneration after injury in the adult animal. While the presence of what we now know to be the basement membrane surrounding skeletal myofibers was first proposed by Bowman in 1840 and while the issue of topographic specificity of reinnervation at the neuromuscular junction (NMJ) was first noted by Cajal in 1928 (see (Sanes and Lichtman, 2001; Sanes, 2003), it was experiments by McMahan and colleagues carried out in the late 1970s that showed that ECM proteins at neuromuscular junction (NMJ), present in the form of a synaptic basal lamina (BL), remained after injury of either the pre- or postsynaptic cell and helped to dictate the topography and presence of synapses on regenerated cell membranes (Letinsky et al., 1976; Marshall et al., 1977; McMahan et al., 1978; Sanes et al., 1978; Burden et al., 1979). Denervation of motor axons, coupled with destruction of the muscle, led to reinnervation of original synaptic sites on the basal lamina, while postsynaptic differentiation of regenerated muscle occurred at the original synaptic sites on the basal lamina even in the absence of the nerve. Such differentiation can be maintained for many months. Thus, the synaptic BL not only marks the location of the NMJ for regenerating

* Author for Correspondence, Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Department of Pediatrics, The Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH 43205, Phone: (614) 722 4072, FAX: (614) 722 5893, Paul.Martin@nationwidechildrens.org.

cells, it provides sufficient trophic support to allow prolonged survival in absence of a synaptic partner. These studies clearly implicated the synaptic ECM as containing essentially indelible markers of synaptic localization and differentiation, which, in turn, has led a number of investigators to search for and identify individual synaptic ECM proteins and their receptors. Due to the space considerations, we apologize in advance for our failure to cite studies, of which there are many, that are not included here. There are a number of previous reviews where one can find additional citations (see (Sanes et al., 1998; Sanes and Lichtman, 2001; Hughes et al., 2006) for general review, (Sanes, 2003) for muscle ECM, (Kummer et al., 2006; Wu et al., 2010) for agrin, (Yurchenco and Patton, 2009) for laminin, (Kadler et al., 2007) for collagen, (Massoulié and Millard, 2009) for acetylcholinesterase, (Engel et al., 1999; Voermans et al., 2008; Farrugia and Vincent, 2010) for neuromuscular disorders, (Martin, 2003; Ervasti and Sonnemann, 2008) for dystrophin-associated complex, (Korkut and Budnik, 2009) for WNTs and (Burden, 1993; Sunesen and Changeux, 2003) for neuregulin).

The neuromuscular synapse has been a favorite of developmental neurobiologists for three reasons: 1. Its large size, about 1000 times that of a typical interneuronal synapse, 2. Its simplicity of patterning, almost all mammalian synapses are ultimately innervated by only one nerve terminal and 3. Its experimental accessibility, which allows imaging and cell manipulation in the living animal. Of course, being an essential synapse that controls voluntary movement and breathing, the NMJ is also very important in its own right. Neuromuscular pathology and dysfunction are involved in a number of human diseases, for example the congenital and autoimmune myasthenias (Engel et al., 2010; Farrugia and Vincent, 2010).

In mammals, including rodents and humans, the NMJ utilizes cholinergic neurotransmission to control muscle movement. Acetylcholine made in motor neurons is packaged into secretory vesicles that reside within the nerve terminal. When the motor nerve, whose cell body resides within the ventral column of the spinal cord or the hindbrain, is excited, an action potential is generated, leading to quantal release of acetylcholine at the NMJ. Nicotinic acetylcholine receptors (AChRs) concentrated in the postsynaptic membrane are activated upon binding acetylcholine to depolarize the muscle membrane, with elevated intracellular calcium levels ultimately causing muscle contraction. Unlike many central nervous system synapses, which must integrate synaptic signals from numerous presynaptic partners, the molecular and cellular architecture of the neuromuscular synapse is designed to insure that neurotransmission occurs with high fidelity each time the motor nerve is excited.

To bring such a robust synaptic structure about, a large number of developmental events must take place. Even so, it still is a bit astounding to think that neuromuscular development in the rodent requires almost a month to be fully completed (Sanes and Lichtman, 2001). Without a doubt, the most striking aspect of NMJ development is the intense concentration of postsynaptic acetylcholine receptors, or AChRs, in the muscle membrane underlying the nerve terminal. During embryogenesis, as myoblasts fuse to form myotubes, synaptic genes, including the subunits of the AChR, are activated to produce high concentrations of AChRs (about $1000/\mu\text{m}^2$). Through a combination of mechanisms (lateral protein migration to synapses, increased mRNA biosynthesis by subsynaptic muscle nuclei, increased protein stability in synaptic regions, increased protein degradation and reduced mRNA expression in non-synaptic regions), AChRs are reorganized and concentrated such that AChR density is $10,000\text{--}20,000/\mu\text{m}^2$ at the adult NMJ while in extrasynaptic regions AChR density is less than $10/\mu\text{m}^2$ (Fambrough, 1979; Sanes and Lichtman, 1999; Sanes and Lichtman, 2001). In addition, AChR subunit composition is altered, with $\alpha_2\beta\gamma\delta$ pentameric AChR channels present in the embryo and $\alpha_2\beta\delta\epsilon$ channels present in the adult (Sunesen and Changeux, 2003). Changed AChR subunit composition alters AChR calcium permeability and channel

open time. This, coupled with the dramatic concentration of AChRs, allows the nerve to excite the skeletal myofiber to membrane potentials well beyond those required to elicit contraction, providing a safety factor for a synapse that must work with high efficiency for the organism to survive.

As the NMJ matures, its shape changes on several levels (Sanes and Lichtman, 2001): 1. The synaptic membrane transforms from a contiguous immature oval plaque to a disjointed pattern of pretzel-like regions. 2. The topography of the pre- and postsynaptic membrane is altered, such that infoldings of the postsynaptic membrane, called secondary folds, align with concentrations of secretory vesicles docked in specialized presynaptic membrane regions called active zones. 3. The extracellular matrix surrounding each skeletal myofiber and within the synaptic cleft forms and matures, both in terms of its density and its molecular constituents, 4. Motor axons that have multiply innervated single myofibers in the embryo are eliminated postnatally such that most myofibers are monoinnervated in the adult, and 5. A synaptic non-myelinating Schwann cell covers the nerve terminal in areas outside the synaptic cleft, capping the region of contact between the nerve terminal and the muscle membrane. These changes coincide with developmental changes that are further removed from the NMJ (sarcomeric patterning and determination of muscle fiber type, muscle growth, adjoining of myofibers to tendons at myotendinous junctions, myelination of motor axons by Schwann cells and development of motor neuron subtypes and pools). Within this complex soup of cellular processes, the extracellular matrix is formed and contributes in important ways to synaptic development.

DEVELOPMENT OF THE SYNAPTIC EXTRACELLULAR MATRIX

The ECM proteins that comprise the synaptic cleft at the NMJ are not fully present when the motor axon first arrives at the skeletal muscle. Shortly thereafter, the muscle begins to synthesize, secrete, and deposit ECM proteins that ultimately comprise a basal lamina that surrounds each and every skeletal myofiber (Figure 1) (Chiu and Sanes, 1984). A basal lamina is an ordered extracellular matrix structure that contains laminin and collagen IV as its main protein constituents, along with heparan sulfate glycosaminoglycans, which in muscle include agrin and perlecan, and other ECM proteins, including tenascin, fibronectin, perlecan, and nidogen (Yurchenco and O'Rear, 1994; Yurchenco et al., 2004). At the NMJ, the deposition of ECM proteins into the synaptic cleft to make the synaptic BL has the effect of appearing to push the nerve away from the skeletal myofiber such that a synaptic cleft of roughly 50nm develops between the cells. Given that many of the proteins present in this region can exceed 50nm, at least along one axis, as individual molecules (for example, laminin, agrin, and collagen IV), the ordering of the synaptic BL could be such that individual ECM proteins contact both the pre- and postsynaptic membrane.

Under the electron microscope, the synaptic BL appears contiguous with the BL surrounding the remainder of the myofiber membrane, but at the molecular level it is quite distinct (Chiu and Sanes, 1984; Engvall et al., 1990; Sanes et al., 1990; Patton et al., 1997). Both major BL proteins, laminin and collagen IV, have different synaptic and extrasynaptic isoforms (Figure 1). In addition, perlecan, agrin, and nidogen are abundantly expressed ECM glycoproteins that have synaptic forms or variants (Ruegg et al., 1992; Jenniskens et al., 2000; Fox et al., 2008). Because members of the laminin and collagen IV families and agrin have been extensively studied in mice at the genetic level, an approach that has led to clearly defined synaptic functions, we will focus primarily on these ECM proteins in this review. This is not an attempt to overlook other important ECM proteins (for example, fibronectin, tenascin, thrombospondin) or the proteins that regulate ECM expression (for example, matrix metalloproteinases and their inhibitors), some of which may have biological roles in neuromuscular biology (Arber and Caroni, 1995; Cifuentes-Diaz et al., 1998; Moscoso et al.,

1998; Voermans et al., 2011), but to focus on aspects of synaptic development for which ECM protein roles have been most clearly defined by human and mouse genetics. Perhaps the best studied of these are the laminins.

Laminins are trimeric proteins composed of three different subunits, with an α , β and γ chain. A new nomenclature has been agreed upon to indicate the subunit composition of individual laminin trimers (for example, laminin $\alpha4\beta2\gamma1$ would be laminin 421 and so on (Aumailley et al., 2005). Myoblasts begin to fuse to form myotubes on or about embryonic day E10 in the rat intercostal muscle. Shortly thereafter, by E11.5, laminin 111, laminin 211 and laminin 511 begin to be synthesized and secreted into the basal lamina surrounding skeletal myofibers in a patchy discontinuous pattern (Patton et al., 1997). Laminin 111 is only expressed for several days during embryogenesis and is by and large only concentrated at the ends of myofibers and myotendinous junctions, while laminin 211 is expressed throughout adulthood, becoming the predominant muscle laminin. The formation of primary myofibers is followed by the formation of secondary myofibers, which coincides with synaptogenesis beginning on about day E13–14. In addition to laminin 211, laminin 411 and laminin 511 become prevalent by E15, at which time a basal lamina sheath surrounds most myofibers. Beginning at E15, the three laminin α chains ($\alpha2$, $\alpha4$, and $\alpha5$) also form trimers with laminin $\beta2$ and laminin $\gamma1$ to make laminin 221, 421, and 521 (Chiu and Sanes, 1984; Patton et al., 1997). These laminins are expressed only at the NMJ due to the synaptic exclusivity of laminin $\beta2$, first identified by Sanes and colleagues as S- (or synaptic) laminin (Hunter et al., 1989). By E18, the $\beta1$ chain of laminin is lost from the NMJ (Chiu and Sanes, 1984; Patton et al., 1997) making laminin 211, 411 and 511 exclusively extrasynaptic. Later, in the first two weeks after birth, laminin $\alpha4$ and laminin $\alpha5$ expression is lost in the extrasynaptic BL, leaving only laminin 211 to surround the extrasynaptic muscle membrane (Chiu and Sanes, 1984; Patton et al., 1997).

Most other ECM proteins, and their receptors, follow one of the developmental expression patterns described for the laminins (Figure 1). For example, muscle-derived agrin and muscle-derived neuregulin follow the same pattern of expression as laminin $\alpha4$ and $\alpha5$. Both of these proteins have extrasynaptic expression at birth that becomes highly concentrated at the NMJ by P14-P21 (Hoch et al., 1993; Moscoso et al., 1995). Ruegg and colleagues have reported that loss of extrasynaptic agrin varies between muscle groups, with some maintaining low levels of extrasynaptic expression into adulthood (Eusebio et al., 2003). Agrin and neuregulin deposited by the motor nerve, by contrast, are confined to the NMJ. MuSK, the tyrosine kinase that responds to neuronal agrin, LRP4, its essential cofactor in agrin signaling, and erbB 2 and 3 kinases, receptors for neuregulin, all show a synaptic expression pattern in the adult animal (Moscoso et al., 1995; Apel et al., 1997; Zhang et al., 2008).

The two principal receptors for both laminins in skeletal muscle are $\alpha7\beta1$ integrin and dystroglycan (Figure 2). There are three splice forms of integrin $\alpha7$ in skeletal muscle (A, B, and C) that differ due to alternative splicing within the intracellular domain (there is splicing within the extracellular domain as well) (Ziober et al., 1993). Integrin $\alpha7A-C$ all form heterodimers with integrin $\beta1$ chains, which in adult skeletal muscle is the $\beta1D$ splice form (van der Flier et al., 1997). Integrin $\alpha7B$ shows an expression pattern equivalent to laminin $\alpha4$ and $\alpha5$, with high extrasynaptic expression at birth and synaptic localization by P14 (Martin et al., 1996). Integrin $\alpha7A$, like laminin $\beta2$, shows an exclusively synaptic expression pattern, but one that becomes evident only beginning at postnatal day 4. Integrin $\alpha7C$ is expressed in a pattern like laminin $\alpha2$, remaining extrasynaptic into adulthood. Integrin $\alpha3\beta1$ is concentrated at the NMJ in active zones within the presynaptic membrane (Cohen et al., 2000), and integrin $\alpha1\beta1$ and $\alpha v\beta1$ are also concentrated at the NMJ (Martin et al., 1996).

Dystroglycan is expressed in both synaptic and extrasynaptic regions of adult myofibers (Ervasti and Campbell, 1991; Matsumura et al., 1992). Unlike integrins, splicing is not an issue for dystroglycan, as the dystroglycan gene has only two exons (Ibraghimov-Beskrovnaya et al., 1993). The complexity in dystroglycan biology comes from posttranslational modifications, in particular glycosylation (Martin, 2003). A large number of genes contribute to glycosylation of α dystroglycan with O-linked mannose chains that are required for laminin (and also agrin and perlecan) binding (Michele et al., 2002; Martin, 2006). The presence of the CT (Cytotoxic T cell) carbohydrate, a glycan structure present on the muscle membrane at the neuromuscular junction (Martin et al., 1999), on α dystroglycan increases binding of both synaptic and extrasynaptic isoforms of laminin (Yoon et al., 2009). Galgt2, the enzyme that synthesizes the synaptic CT carbohydrate on α dystroglycan (Yoon et al., 2009), and the CT glycan itself, are expressed in extrasynaptic regions at birth and become confined to the NMJ by P14 (Martin et al., 1999; Hoyte et al., 2002). Some heparan sulfate glycosaminoglycan (GAG) structures show a similar developmental expression pattern to the CT carbohydrate, suggesting that glycosaminoglycans on synaptic proteoglycans (e.g. agrin and perlecan) are different than the glycosaminoglycans on their extrasynaptic forms (Jenniskens et al., 2000).

Like laminin $\alpha 2$, Collagen IV ($\alpha 1$)₂($\alpha 2$) trimers are present along the entirety of the muscle BL from an early embryonic stage (Sanes et al., 1990). By contrast to laminins, collagen IV ($\alpha 3$, $\alpha 4$, $\alpha 5$), collagen IV ($\alpha 5$)₂($\alpha 6$), both also secreted basal lamina components, and collagen XIII, a transmembrane collagen localized at the plasma membrane, are not expressed until after birth and are only found at the NMJ, with clear expression being evident for all at P21 (Miner and Sanes, 1994; Fox et al., 2007; Latvanlehto et al., 2010). Collagen VI, an extracellular beaded filament-forming collagen (Kadler et al., 2007), is present in the reticular lamina that surrounds the extrasynaptic BL in adult muscle (Lampe and Bushby, 2005). As the reticular lamina is not present at the NMJ, collagen VI is not present at the synapse. Another collagen-like molecule is ColQ, the non-enzymatic synaptic subunit of acetylcholinesterase (AChE) (Massoulié and Millard, 2009). ColQ is exclusively localized at the synapse, becoming present shortly after the arrival of the motor axon (Chiu and Sanes, 1984; Rotundo, 2003).

THE THREE “A”s IN THE SYNAPTIC AChR TRIUMVIRATE - AGRIN, ACTIVITY AND ARIA

Most early studies of NMJ development focused on the dramatic concentration of postsynaptic acetylcholine receptors (AChRs) in the muscle membrane. This search was greatly facilitated by access to α bungarotoxin, a 74 amino acid snake protein isolated from *Bungaris multicinctus*, that bound with specific and high, almost irreversible, affinity to muscle AChRs (Lee et al., 1967). Early studies pointed to three components important for the concentration of AChRs-Agrin, Activity and ARIA. Agrin is the synaptic ECM protein best understood to play an essential role in synaptic development, but consensus on its mechanism of action has shifted in the years since its original purification and cloning. Agrin was originally purified from the marine ray, *Torpedo californica*, as a factor that stimulated the clustering of acetylcholine receptors (AChRs) in the membrane of cultured skeletal myofibers (Godfrey et al., 1984; Wallace et al., 1985; Nitkin et al., 1987). A single agrin gene was cloned and identified as an approximately 400kDa heparan sulfate glycosaminoglycan, with the glycosaminoglycan chains representing about half the molecular weight of the molecule (Rupp et al., 1991; Tsim et al., 1992; Tsen et al., 1995) (Figure 2). Still other glycosylation domains showed the presence of N-linked glycosylation and mucin-like regions with high densities of O-linked sugars. Agrin is a roughly linear 95nm rod-like protein (Denzer et al., 1998). At the N-terminus, agrin contains a unique splice site allowing for a transmembrane domain in neurons as well as a splice form that can

be transported down the motor axon and secreted at the motor nerve terminal (Magill-Solc and McMahan, 1990; Magill-Solc and McMahan, 1990; Denzer et al., 1998; Burgess et al., 1999; Burgess et al., 2000). The N-terminal half of the molecule also contains a binding domain for laminin and a nine follistatin-like repeats (Rupp et al., 1991; Tsim et al., 1992; Denzer et al., 1998).

The AChR aggregating activity of agrin was shown to be present in the C-terminal half of the molecule, which contains four EGF-like repeats and three laminin-like G domains (LG1-3, Figure 2) (Rupp et al., 1991; Ruegg et al., 1992; Tsim et al., 1992). LG3 is the domain that is essential for the *in vitro* AChR aggregation activity of agrin (Gesemann et al., 1995; Campanelli et al., 1996; Gesemann et al., 1996). Moreover, one of two neuron-specific exons must be spliced into the z splice site in LG3, controlled by the neuron-specific splicing factors Nova 1 and 2 (Ruggiu et al., 2009), for agrin to have high AChR clustering activity. Mutagenesis of the z splice exons has further defined the essential amino acids required (Scotton et al., 2006). This LG3 domain is also required for agrin binding to the $\alpha 3$ subunit of the sodium-potassium ATPase (Hilgenberg et al., 2006). The LG2 domain binds α dystroglycan (Bowe et al., 1994; Campanelli et al., 1996; Gesemann et al., 1996; Gesemann et al., 1998). LG2 confers higher affinity agrin binding to muscle cells, which alters its potency in inducing AChR clustering (Campanelli et al., 1996; Gesemann et al., 1996). The presence of LG1 increases further agrin binding to α dystroglycan and agrin potency in inducing AChR clustering on cultured muscle cells (Gesemann et al., 1996). This may be mediated by one of several integrins (e.g. $\alpha v \beta 1$) that bind to this domain (Martin and Sanes, 1997; Burgess et al., 2002). At least one EGF repeat (EGF4) is also a site for O-fucosylation by Pofut1 (Protein O-fucosyltransferase 1) that can alter the muscle form of agrin's bioactivity (Kim et al., 2008). Ectopic expression of agrin can induce postsynaptic specializations *in vivo* (Cohen et al., 1997; Jones et al., 1997; Meier et al., 1998; Meier et al., 1998; Rimer et al., 1998) and deletion of agrin, even deletion of only the z splice exons, leads to aberrant neuromuscular development, including increased motor nerve branching, decreased apposition of pre- and postsynaptic specializations, dramatically fewer AChR clusters in the postsynaptic membrane and paralysis (Gautam et al., 1996; Burgess et al., 1999).

These experiments all pointed to agrin being an important inducer of AChR clustering in the postsynaptic membrane, but more recent work has defined agrin as a stabilizer of the postsynaptic membrane rather than as an inducer of it. Classic studies from Burden and colleagues and Lee and colleagues showed that mice lacking the motor nerve (the phrenic nerve, via deletion of DNA topoisomerase II β or the transcription factor HB9) or mice lacking the neurotransmitter acetylcholine (via deletion of choline acetyltransferase) maintain ectopic expression of postsynaptic specializations along the majority of the myofiber membrane (Yang et al., 2000; Lin et al., 2001; Yang et al., 2001; Brandon et al., 2003). Such specializations, while present in the middle region of the muscle during embryogenesis, normally dissipate by birth, leading to a concentrated endplate band of postsynaptic AChRs. Thus, the muscle pre-patterns AChR-rich postsynaptic membranes rather than the nerve instructing the muscle to do so. While mice lacking agrin showed ectopic AChR aggregates before birth, these were lost more quickly than in normal muscles, suggesting that agrin counteracted the pre-patterning of AChR-rich postsynaptic domains within the muscle membrane. Mice deficient in choline acetyltransferase (ChAT) rescued the agrin null phenotypes, with double mutant mice having normal postsynaptic AChR density and relatively normal innervation (Lin et al., 2005; Misgeld et al., 2005). This supports a model wherein agrin serves to stabilize and offset the dissipation of postsynaptic membrane formation normally driven by muscle activity (the second A). This AChR dispersing activity of acetylcholine is mediated in part by activation of serine/threonine cyclin-dependent kinase 5 (Cdk5), calpain and calcium/calmodulin protein kinase II (Tang

et al., 2004; Fu et al., 2005; Lin et al., 2005; Chen et al., 2007). Cdk5-null mice phenocopy ChAT null animals in their formation of ectopic pre-patterned AChR aggregates in muscle, and Cdk5 inhibitors can block the effects of acetylcholine addition to muscle cells (Fu et al., 2005; Lin et al., 2005). Thus, while *in vitro* studies of agrin activity in inducing AChR clustering are legion (and true), such clusters form without agrin *in vivo*, and agrin instead serves to locally counteract the negative dispersal of postsynaptic AChRs by activity.

Studies by Yancopoulos and colleagues implicated MuSK, a muscle transmembrane tyrosine kinase (Jennings et al., 1993), as the receptor for agrin (DeChiara et al., 1996). Mice lacking MuSK have no postsynaptic membranes, even during early development and even in the absence of acetylcholine. Importantly, MuSK is also essential for the pre-patterning of AChRs in skeletal muscle (Lin et al., 2001) and overexpression of MuSK in muscle can lead to ectopic synapse formation, suggesting that such pre-patterning is instructive for defining the ultimate sites of innervation (Kim and Burden, 2008). This also appears to be true in zebrafish, where pre-patterned, aneural, postsynaptic AChR aggregates ultimately become innervated by motor neurons (Flanagan-Steet et al., 2005; Panzer et al., 2005).

Addition of agrin to myofibers stimulates the phosphorylation of tyrosine residues on MuSK in cultured cells, demonstrating MuSK's ability to respond to agrin, but agrin does not bind directly to MuSK (Glass et al., 1996). Rather, agrin binds Lrp4 and activates MuSK via an agrin-Lrp4-MuSK signaling complex (Kim et al., 2008; Zhang et al., 2008). Lrp4 is a member of the low-density lipoprotein receptor family that is concentrated at the NMJ and contains, like other Lrps, an extracellular protein motif that is very densely glycosylated (May et al., 2007). Mice lacking Lrp4, like mice lacking MuSK, fail to make proper NMJs (Weatherbee et al., 2006), and expression of Lrp4 in non-muscle cells can recover MuSK activation by agrin (Kim et al., 2008; Zhang et al., 2008).

MuSK interacts with a number of important cytoplasmic proteins to carry out its signaling functions (Figure 3). These include adaptor protein Dok7 (downstream of tyrosine kinase 7) (Okada et al., 2006; Inoue et al., 2009; Bergamin et al., 2010), dishevelled 1 (Dvl1) and p21-activated kinase (Pak1) (Luo et al., 2002), and tumourous imaginal discs protein (Tid1) (Linnoila et al., 2008). Likewise, rapsyn (Sobel et al., 1977; Sealock et al., 1984; Frail et al., 1988), a myristylated muscle protein that binds in a one-to-one stoichiometry to the AChR (LaRochelle and Froehner, 1986), interacts with MuSK (Apel et al., 1997) and is essential for AChR aggregation (Gautam et al., 1995; Borges et al., 2008). Rapsyn interactions can be altered by calpain, a muscle protease (Chen et al., 2007). The small G proteins Rac and Rho and geranylgeranyltransferase I, an enzyme that can modify and activate G proteins via prenylation, also play important roles in this process (Luo et al., 2003; Weston et al., 2003), as does APC (adenomatous polyposis coli), an actin-binding protein (Wang et al., 2003).

Agrin binding to Lrp4-MuSK stimulates MuSK autophosphorylation on tyrosine 553 near the transmembrane region, beginning the process of MuSK signaling (Watty et al., 2000). This recruits Dok7 dimers, which cross-link and dimerize MuSK subunits along with Crk and Crk-L (Herbst and Burden, 2000; Herbst et al., 2002; Till et al., 2002; Inoue et al., 2009; Bergamin et al., 2010; Hallock et al., 2010). MuSK then autophosphorylates tyrosines 750, 754 and 755. This is thought to release the auto-inhibitory domain within the cytoplasmic tail, allowing substrate binding (Watty et al., 2000; Till et al., 2002). Casein kinase 2 (CK2) phosphorylates serines on MuSK (Cheusova et al., 2006), enhancing AChR clustering, and the tyrosine kinases Src and Fyn affect AChR β -subunit phosphorylation in a MuSK-dependent manner (Smith et al., 2001; Mittaud et al., 2004; Sadasivam et al., 2005). Abelson kinase (Abl), a tyrosine kinase, and Shp2 (Src homology 2-containing protein tyrosine phosphatase 2), a tyrosine phosphatase, have been suggested to provide positive and

negative feedback loops, respectively, for MuSK phosphorylation (Finn et al., 2003; Mittermaier et al., 2004; Madhavan et al., 2005; Zhao et al., 2007).

Overexpression of MuSK is sufficient to induce ectopic AChR aggregates, even in the absence of agrin, and MuSK overexpression expands the topographic zone of innervation in the myofiber membrane (Kim and Burden, 2008). This may be the result of spontaneous MuSK autoactivation through increased MuSK-MuSK associations. In such muscles, ectopic AChR aggregates can become innervated, even when far removed from the normal sites of innervation, suggesting that MuSK expression, and thereby increased MuSK activity, pre-patterns sites within the postsynaptic membrane for innervation by nerve terminals. How is this pre-patterning of MuSK expression normally achieved? Expression of MuSK, and thereby its degree of autoactivation, is most likely controlled at the transcriptional and posttranslational levels. As for transcription, the MuSK gene contains an E box DNA binding element for the transcription factor myogenin, which suppresses transcription of genes in extrasynaptic nuclei of adult myofibers (Tang et al., 2006), and an N box DNA binding element (Lacazette et al., 2003), which induces transcription of genes in synaptic nuclei via Ets factors, which are, in part, activated by neuregulin (Burden, 1993). The late onset expression of myogenin in embryogenesis may help to dictate the suppression of MuSK, thereby tying the topography of innervation to muscle differentiation. Myogenin expression, in turn, can be controlled by histone deacetylase 4 (HDAC4), which, when deleted, increases extrasynaptic AChR clustering and expression of synaptic genes (Tang et al., 2009). As for posttranslational regulation, MuSK contains a carboxyterminal motif that can associate with an E3 ubiquitin ligase, PDZRN3 (Lu et al., 2007) and putative ariadne-like ubiquitin ligase (PAUL) (Bromann et al., 2004), both of which may also control protein levels, as may association with N-ethylmaleimide sensitive factor (NSF) (Zhu et al., 2008) and calpain (Hezel et al., 2010). Mutation of the N-linked glycosylation sites on MuSK can also alter protein stability (Watty and Burden, 2002). While agrin is a very large ECM protein, a wealth of biochemical and genetic studies point to the clear importance of the Agrin-Lrp4-MuSK signaling pathway in stabilizing the postsynaptic membrane under the nerve terminal. These are supported by the findings of human mutations in agrin, MuSK and MuSK-binding proteins that cause congenital myasthenias (Huze et al., 2009; Engel et al., 2010; Farrugia and Vincent, 2010).

The third A in the AChR triumvirate is ARIA-coined Acetylcholine Receptor Inducing Activity for its ability to stimulate AChR mRNA levels in cultured muscle cells (Falls et al., 1993). ARIA is more commonly called neuregulin (NRG) (though it goes by other names as well, including glial growth factor (GGF), neu differentiation factor (NDF), and heregulin (HRG) (Lemke and Brockes, 1984; Holmes et al., 1992; Marchionni et al., 1993). Neuregulin activity is associated with its extracellular EGF domain, which activates dimeric forms of the erbB2-erbB3 or erbB2-erbB4 transmembrane tyrosine kinase (Gassmann and Lemke, 1997). The erbB kinases are present in skeletal muscles and/or in Schwann cells (Altiok et al., 1995; Chu et al., 1995; Goodearl et al., 1995; Jo et al., 1995; Moscoso et al., 1995; Sandrock et al., 1995; Zhu et al., 1995; Rimer et al., 1998; Lemke, 2006). Neuregulin has many biological activities. Perhaps most importantly here, it is essential for nerve-dependent survival and function of Schwann cells (Trachtenberg and Thompson, 1996; Lemke, 2006).

Three groups of studies originally pointed to neuregulin as also being important for the increased concentration of AChR mRNAs in subsynaptic muscle nuclei: 1. Motor neurons synthesize, transport, and secrete neuregulin protein into the synaptic ECM at the NMJ (Han and Fischbach, 1999), 2. Addition of neuregulin to cultured myotubes increases transcription of AChR mRNAs (Schaeffer et al., 2001) and 3. Mice heterozygous for deletion of neuregulin-1, mice deleted for neuregulin receptors (erbB kinases 2 or 3), where cardiac

defects are transgenically rescued and mice overexpressing dominant activated forms of neuregulin receptors in skeletal muscles all have altered AChR transcription, altered neuromuscular development, or are myasthenic (Sandrock et al., 1997; Woldeyesus et al., 1999; Lin et al., 2000; Ponomareva et al., 2006). Other experiments subsequently pointed to the fact that neuronally derived neuregulin, indeed the whole nerve, is indispensable for concentration of AChR mRNAs and the transcription of synaptic genes (Lin et al., 2001; Yang et al., 2001). In addition, motor neuron- or muscle-specific knockouts of neuregulin, or skeletal muscle-specific knockouts of its receptors, erbB2 and/or erbB4, cause, at best, only a slight deficit in synaptic AChR transcription (Leu et al., 2003; Escher et al., 2005; Jaworski and Burden, 2006). These mice have relatively normal NMJ development and neurotransmission, though other findings, for example defects in muscle spindle formation, can be present (Leu et al., 2003). Thus, neuregulin-deficient phenotypes, when found, most likely result from its effects on Schwann cell development and survival rather than from effects of its secretion from the nerve and signaling to skeletal muscle.

SYNAPTIC LAMININS – DEFINING SYNAPTIC ULTRASTRUCTURE

Laminin 211, the predominant extrasynaptic muscle laminin, and laminin 211-associated membrane proteins, are essential for the maintenance of the integrity of the skeletal myofiber membrane (Mayer et al., 1997; Hayashi et al., 1998; Blake et al., 2002; Durbeek and Campbell, 2002; Michele and Campbell, 2003; Barresi and Campbell, 2006; Martin, 2006; Ervasti and Sonnemann, 2008; Chandrasekharan and Martin, 2010; Hara et al., 2011). Of this there can really be no doubt. Mice and humans deficient in laminin $\alpha 2$ (the 2 in laminin 211) have congenital muscular dystrophy, mice and humans lacking enzymes that make glycans on α dystroglycan that are necessary for laminin 211 binding have muscular dystrophy, mice lacking dystroglycan in skeletal muscles have muscular dystrophy (as can humans with a particular missense mutation in dystroglycan), and mice and humans lacking cytoplasmic dystroglycan binding proteins (e.g. dystrophin, Plectin 1) have muscular dystrophy. Mice and humans lacking the principal laminin binding integrin in skeletal muscle, integrin $\alpha 7\beta 1$, also have muscular dystrophy.

Overexpression of certain ECM proteins (laminin 111 (Gawlik et al., 2004; Rooney et al., 2009; Rooney et al., 2009) or agrin (Moll et al., 2001; Bentzinger et al., 2005), or overexpression of synaptic laminin-associated proteins or their modifiers (Galgt2, a synaptic enzyme that glycosylates α dystroglycan (Nguyen et al., 2002; Xu et al., 2007; Xu et al., 2009), integrin $\alpha 7\beta 1$, a synaptic integrin (Burkin et al., 2001; Burkin et al., 2005), or utrophin, a synaptic orthologue of dystrophin (Deconinck et al., 1997; Rafael et al., 1998; Tinsley et al., 1998) all can functionally compensate for the loss of members of the extrasynaptic laminin 211 complex in skeletal muscles and inhibit muscle disease. These experiments suggest that synaptic ECM proteins serve structural roles in maintaining the synaptic membrane akin to what their extrasynaptic counterparts do in the rest of the muscle cell. As the synaptic basal lamina comprises only about 0.1% of the myofiber membrane, loss of synaptic laminin chains does not lead to muscle damage, but such loss does lead to profound changes in synaptic ultrastructure.

At the NMJ, laminin 221, 421 and 521 are defined as uniquely synaptic by either the expression of a synaptic α chain (laminin $\alpha 4$ or laminin $\alpha 5$), which occurs postnatally, or by synaptic expression of laminin $\beta 2$, which occurs embryonically (Figure 1) (Patton et al., 1997). As laminin $\beta 2$ is present in all three synaptic laminin trimers, it is perhaps not surprising that mice lacking laminin $\beta 2$ show aberrant NMJ development (Noakes et al., 1995). In laminin $\beta 2$ -deficient mice, the three cells of the NMJ fail to develop their proper alignment. Instead, the synaptic Schwann cell sends processes between the nerve terminal and muscle to invade the synaptic cleft, removing about half the extent of normal nerve-

muscle interaction. This may be due to loss of laminin 521. Schwann cells show little ability to migrate on laminin 521 (Cho et al., 1998; Patton et al., 1998), therefore its absence may in effect remove the synaptic break on Schwann cell migration. In addition, synaptic ultrastructure fails to form properly in laminin β 2-deficient mice (Noakes et al., 1995). Secondary folds in the postsynaptic membrane are reduced, as are active zones in the presynaptic membrane. Moreover, both structures, when present, are not precisely aligned with one another. Consistent with ultrastructural changes, laminin β 2-deficient mice have deficits in endplate potentials consistent with their altered synaptic architecture (Noakes et al., 1995). Almost all developmental phenotypes become significant shortly after birth (by P7) (Fox et al., 2007). To some extent, laminin β 2-dependent phenotypes may overlap with FGF-dependent phenotypes, as FGFR2/Lam β 2 double mutants show more pronounced changes (Fox et al., 2007).

Laminin β 2 is confined to the synapse via its secretion from skeletal myofibers through a combination of mechanisms, which include concentration of laminin β 2 mRNAs in subsynaptic nuclei and the synaptic targeting of laminin β 2-containing proteins (Martin et al., 1995; Moscoso et al., 1995; Miner et al., 2006). Skeletal myofibers cultured in the absence of nerves make postsynaptic membranes where laminin β 2 becomes exclusively localized, even when the protein is overexpressed by all muscle cell nuclei (Martin et al., 1995). Likewise, transgenic mice made to overexpress laminin β 2 in all skeletal myofiber nuclei nevertheless concentrate laminin β 2 exclusively at the NMJ (Miner et al., 2006). Thus, the laminin β 2 protein is capable of driving its own synaptic localization. Synaptic localization requires a region near the C-terminus of laminin β 2 within the coiled-coil domain that interacts with the other laminin chains (Martin et al., 1995).

Nishimune, Sanes, and Carlson identified a presynaptic receptor for laminin β 2, the voltage-gated calcium channel (Nishimune et al., 2004). N- and P/Q-type voltage-gated calcium channels, the subtypes present in the motor nerve terminal during early and late NMJ development, respectively, bind laminin β 2 via their eleventh extracellular loop (in $Ca_v2.2$ or $Ca_v2.1$) (Nishimune et al., 2004). This loop binds the region of laminin β 2 containing the LRE tripeptide originally shown to be the adhesion site for motor neurons (Hunter et al., 1989). Mice deficient in N-type calcium channels copy the loss of active zones seen in laminin β 2-deficient mice (Noakes et al., 1995; Nishimune et al., 2004). This phenotype could also be induced by injection of a peptide from the 11th extracellular loop of the N-type channel into wild type NMJs (Nishimune et al., 2004). Similar findings have been found for sensory innervation of the skin in *Xenopus laevis* (Sann et al., 2008). Mice deficient in both N- and P/Q- calcium channels show a further reduction in active zones proteins, including Bassoon, Piccolo, and CAST/Erc2, supporting the presence of a direct laminin β 2-calcium channel-cytoskeletal active zone scaffold (Chen et al., 2011). The loss of active zones in laminin β 2 and calcium channel mutant mice is akin to what occurs in Eaton-Lambert myasthenic syndrome, where patients develop autoantibodies to voltage-gated calcium channels (Farrugia and Vincent, 2010). It is possible that some such autoantibodies disrupt laminin β 2-calcium channel interactions. Humans with mutations in laminin β 2 (LAMB2) can also develop congenital myasthenia. This disease has ultrastructural changes at the NMJ similar to those found in laminin β 2 deficient mice (Maselli et al., 2009).

Receptors for laminin β 2 on the skeletal muscle membrane are not well understood, though laminins containing the β 2 chain bind postsynaptic membranes even in the absence of nerves (Martin et al., 1995). While the β chains of laminin do not have the laminin LG domains required for binding to α dystroglycan and many integrins, it would not be surprising if laminin β 2 helped to define such interactions through its interactions with laminin α chains. There is at least one report of a β 2-containing laminin (laminin 421) binding α 3 integrin (Carlson et al., 2010), which is also concentrated within active zones

(Cohen et al., 2000). Another issue with phenotype interpretation is that laminin β 1, which is normally excluded from the synaptic ECM in the adult (Chiu and Sanes, 1984), is present at the NMJ in laminin β 2-deficient animals (Martin et al., 1996). Thus, aberrant expression of extrasynaptic laminins (211 and 411) at the NMJ in laminin β 2 deficient mice may contribute to the phenotypes seen.

Work by Patton, Sanes and colleagues on laminin α 4-deficient mice has shown that the laminin α 4 protein is essential for the proper alignment of presynaptic active zones with the crests of AChR-rich secondary folds in the postsynaptic membrane (Patton et al., 2001). Laminin α 4, as laminin 421, is restricted to small domains within the synaptic BL at the crests of the secondary folds, where such alignments take place. Mice lacking laminin α 4, unlike mice lacking laminin β 2, show normal numbers of pre- and postsynaptic specializations with regard to active zones and secondary folds, but these structures are no longer precisely aligned with one another (Patton et al., 2001). The misalignment of active zones and secondary folds ultimately is associated with alterations in synaptic geometry more commonly found in aged NMJs (Balice-Gordon and Lichtman, 1990; Valdez et al., 2010). For example, laminin α 4-deficient nerve terminal branches appear to atrophy, showing thinner varicosities even at young ages (Patton et al., 2001). The receptors responsible for laminin α 4-dependent phenotypes are not well understood. The direct binding of voltage-gated calcium channels to laminin β 2 (Nishimune et al., 2004) and its role in active zone development (Noakes et al., 1995; Nishimune et al., 2004; Chen et al., 2011) suggests that laminin α 4-deficient mice could merely be laminin β 2 hypomorphs. This could result from reduced, but not absent, expression of laminin β 2 in laminin α 4-deficient mice, as laminin 521 and 221 would still be present (Noakes et al., 1995; Patton et al., 1997; Patton et al., 2001). Laminin α 4 also plays a role in controlling Schwann cell proliferation and myelination, which could impact NMJ development (Yang et al., 2005).

Analysis of the role of laminin α 5 has been complicated by additional phenotypes (exencephaly, syndactyly, and dysmorphogenesis of the placenta) that cause neonatal death when this laminin is deleted in the whole mouse (Miner et al., 1998). A conditional muscle-specific deletion was made to more easily assess the role of laminin α 5 at the NMJ (Nishimune et al., 2008). The topological maturation of AChR clusters (from plaque to pretzel) was delayed in the absence of muscle laminin α 5, and this was accentuated significantly in mice lacking both muscle laminin α 5 and laminin α 4 (Nishimune et al., 2008). Interestingly, expression of a chimeric laminin α 1/ α 5 transgenic protein, where the LG3-LG5 domains of laminin α 1 replaced the respective regions in laminin α 5, failed to rescue laminin α 5 deficient phenotypes (Nishimune et al., 2008). While the topological maturation defects observed in muscle-specific laminin α 5-deficient mice were more subtle than those in mice lacking laminin β 2 (Noakes et al., 1995), they add support to the notion that laminin α chains may, either directly or by proxy, impact postsynaptic development as well as presynaptic development. Laminin 511 can also interact with SV2 (Son et al., 2000), a synaptic vesicle transmembrane protein, and laminin 521 can associate with and prevent the migration of Schwann cells and motor axons (Cho et al., 1998; Patton et al., 1998). Thus, laminin α 5 may also have presynaptic roles, though the impact of those roles on synaptic ultrastructure appears to be muted.

Trimeric laminins have an intrinsic ability to polymerize into an ECM, but certain proteins can both facilitate polymerization or cross-link laminin, once present, with other ECM proteins (Yurchenco and Patton, 2009). Nidogen, also known as entactin, provides such a cross-link between laminins and collagen IV (Fox et al., 1991; Aumailley et al., 1993). Nidogen 1 and 2 are 150kDa proteins comprised mostly of three globular domains that make a protein of about 40nm in length. The G2 domain binds collagen IV while the G3 domain binds laminin γ 1 (Reinhardt et al., 1993; Poschl et al., 1996). There is good evidence that

nidogen 2 is synaptically expressed at the adult NMJ (Chiu and Ko, 1994; Fox et al., 2008). Nidogen 2 is present in the entire extrasynaptic BL at birth and becomes confined to the NMJ by the third postnatal week (Figure 1). The absence of nidogen 2, however, does not alter expression of any other synaptic ECM proteins; nidogen 2 is present in mice lacking synaptic laminins ($\beta 2$, $\alpha 4$, or $\alpha 5$) or synaptic collagen IVs ($\alpha 3$ - $\alpha 6$), and all of these proteins are present in mice lacking nidogen 2 (Fox et al., 2008). Nevertheless, mice deficient in nidogen 2 show subtle changes in the postsynaptic structuring of AChRs at the NMJ, making NMJs seem more immature in appearance (Fox et al., 2008). This phenotype is variable between muscle groups. As some muscles (e.g. extensor digitorum longus) have almost no abnormal synapses, this is clearly not an essential protein for synaptogenesis.

Almost all laminin α chains also bind α dystroglycan and members of the $\beta 1$ family of integrins (Figure 2) (Yurchenco et al., 2004). Integrin $\alpha 7\beta 1$ is the predominant muscle integrin, including at the NMJ (Song et al., 1992; Ziober et al., 1993; Martin et al., 1996). Several early studies suggested that integrin $\alpha 7$ altered agrin-induced AChR clustering *in vitro* (Burkin et al., 1998; Burkin et al., 2000). Mice lacking integrin $\alpha 7$, however, show no significant neuromuscular abnormalities, though they do develop an unusual form of muscular dystrophy (Mayer et al., 1997). Expression of some synaptic integrin $\alpha 7$ splice forms, however, is altered in laminin $\beta 2$ deficient mice, suggesting a more direct synaptic integrin-laminin connection (Martin et al., 1996). Mice lacking other synaptic integrin α chains also do not appear to have NMJ phenotypes. Such lack of effects may be due to molecular compensation between different integrin α chains. Tissue-specific deletion of integrin $\beta 1$, which is required for expression of almost all muscle integrin α chains (as integrins are $\alpha\beta$ heterodimers), has been a means of getting beyond such problems (Schwander et al., 2003; Schwander et al., 2004). Interestingly, early loss of $\beta 1$ integrin in muscle impaired myoblast fusion and yielded aberrant myotubes with altered costameric patterning (Schwander et al., 2003). Those myofibers that were formed, however, did not show altered expression of muscle ECM proteins or receptors (e.g. laminin $\alpha 2$, collagen IV, nidogen, perlecan, dystroglycan) (Schwander et al., 2003). Mice with muscles lacking integrin $\beta 1$ fail to be innervated, despite pre-patterning of AChRs in muscle cells, and die perinatally (Schwander et al., 2004). This experiment strongly suggests that muscle $\beta 1$ integrins have important roles in NMJ development. Specific deletion of $\beta 1$ integrin in motor neurons, by contrast, appears to have no impact on NMJ development (Schwander et al., 2004). Thus, the role of integrins in the presynaptic membrane remains unclear.

Like $\beta 1$ integrin, deletion of dystroglycan results in embryonic lethality when this gene is removed from the whole animal (Williamson et al., 1997). Myotube-specific deletion of dystroglycan results in muscular dystrophy (Cohn et al., 2002). Dystroglycan deletion in specific myofibers caused neuromuscular abnormalities that suggested a role for dystroglycan in postsynaptic development (Cote et al., 1999). Interestingly, muscle cells lacking laminin $\alpha 4$ and laminin $\alpha 5$ also have reduced expression of synaptic dystroglycan at AChR-rich regions, while muscle cells lacking dystroglycan have altered AChR patterning similar to cells lacking laminin $\alpha 4$ and $\alpha 5$ (Nishimune et al., 2008). Unfortunately, laminin $\alpha 4$ and $\alpha 5$ are often upregulated in dystrophic skeletal muscles (Patton et al., 1999), making it difficult to assess their role in dystroglycan deficiency *in vivo*. Laminin LG domains are usually removed from laminin to study their interaction with receptors such as α dystroglycan, as native laminin is a spontaneously forming polymer. Such studies show that recombinant laminin LG α chains bind α dystroglycan and that differential glycosylation of α dystroglycan can alter such binding. For example, laminin LG1-5 domains from laminin $\alpha 2$ (LG1-5($\alpha 2$)), the predominant integrin/dystroglycan-binding region on the predominant extrasynaptic laminin, binds the extrasynaptic glycoform of α dystroglycan one hundred times better than laminin LG1-5 ($\alpha 4$), a synaptic laminin (Talts et al., 1999; Talts et al., 2000). By contrast, binding of synaptic LG1-5($\alpha 4$) and LG1-5($\alpha 5$) laminin are increased

significantly more than binding of LG1-5(α 2) when α dystroglycan is glycosylated with the synaptic CT carbohydrate (Yoon et al., 2009). Moreover, transgenic overexpression of Galgt2, the enzyme that creates the synaptic CT carbohydrate, in skeletal myofibers stimulates CT glycosylation of α dystroglycan along the extrasynaptic membrane and induces ectopic overexpression of laminin α 4 and laminin α 5 (Xia et al., 2002), both normally synaptic dystroglycan-binding proteins. This upregulation likely involves a combination of increased laminin transcription and increased laminin membrane affinity or ECM stability. As a group, the ectopic overexpression of this complex of synaptic laminins, synaptically glycosylated dystroglycan, and utrophin (and other synaptic dystrophin surrogates), driven by Galgt2, can functionally compensate for loss of laminin α 2 or dystrophin in the extrasynaptic muscle membrane (Nguyen et al., 2002; Xu et al., 2007; Martin et al., 2009; Xu et al., 2009). Loss of these extrasynaptic muscle proteins, for example in laminin α 2 deficient dy^W mice or in dystrophin-deficient mdx mice, normally leads to muscular dystrophy, and expression of the Galgt2 transgene inhibits muscle damage from occurring in these disease models.

Laminin signaling via dystroglycan and laminin/collagen signaling via integrins are markedly complex processes, well beyond the scope of this review, however, we will discuss here some of the protein components in these pathways proven relevant to changes in synaptic development and structure (Figure 3). In particular, deletion of cytoplasmic dystroglycan-binding proteins has suggested a role for intracellular dystroglycan-binding proteins in the NMJ ultrastructure and development. In the extrasynaptic membrane, laminin 211 binds α dystroglycan on the outside of the myofiber membrane and dystrophin binds β dystroglycan on the intracellular side. Dystrophin, the 400kDa protein whose absence give rise to Duchenne muscular dystrophy (Hoffman et al., 1987; Koenig et al., 1987), links dystroglycan and associated proteins in the membrane to the F-actin cytoskeleton via a variety of molecular interactions, including binding to other cytoskeleton binding proteins (plectin 1 and ankyrin), cytoplasmic DAG complex proteins (syntrophins and dystrobrevins), and signaling molecules (neuronal nitric oxide synthase, nNOS) (Blake et al., 2002). While dystrophin is also present at the NMJ, a dystrophin orthologue called utrophin is uniquely present at the synapse (Ohlendieck et al., 1991). Utrophin is very similar in protein domain structure to dystrophin (Love et al., 1989) and binds a similar cohort of molecules, but some of these, for example, β 2 syntrophin and α 1 dystrobrevin (Peters et al., 1997; Peters et al., 1998), like utrophin, are either uniquely present or are highly concentrated at the NMJ. Mouse genetics has shown that deletion of utrophin, syntrophins, or dystrobrevins all give rise to changes in NMJ structure akin to those observed in dystroglycan-deficient muscles, suggesting that these synaptic proteins translate structural information and/or signals from laminins in the synaptic BL through the postsynaptic membrane (Figure 3) (Deconinck et al., 1997; Grady et al., 1997; Cote et al., 1999; Adams et al., 2000; Grady et al., 2000). There are a variety of other proteins that can associate with dystroglycan (for example, Grb2, Rapsyn, Plectin, Ezrin) or that can signal from laminin via dystroglycan (for example, Src, MAP kinase, Akt) that could be involved in NMJ development. Similarly, there are a host of cytoplasmic and membrane integrin-associated proteins (for example, Talin, Vinculin, Paxillin, Focal adhesion kinase (FAK), Alpha actinin, CD47, etc.) (Figure 3) and related signaling molecules (for example Grb2, Cib2, Crk, Src, Fgr, Ras, Rho, PI-3 Kinase, MAP Kinase) that may be involved in laminin/collagen signaling at the NMJ. To our knowledge, there has been no definition of specific intracellular integrin protein binding interactions in mammals that define specific synaptic laminin- or collagen IV-integrin NMJ functions, though these may certainly exist. Because deletion of all β 1 integrins in muscle has been very complicated to analyze due to changes in muscle development and lack of innervation (Schwander et al., 2003; Schwander et al., 2004), it is perhaps not surprising that these integrin-associated proteins have not been more intensively explored regarding NMJ development.

THE SYNAPTIC COLLAGENS – MATURATION OF THE SYNAPSE

In addition to laminin, the other major class of muscle BL proteins are the non-fibrillar collagens of the collagen IV family (Yurchenco and Patton, 2009). Collagen IV proteins are approximately 400nm long threadlike coils comprised of three very homologous polypeptide chains (Yurchenco and O'Rear, 1994). Each collagen IV trimer contains an N-terminal cysteine-rich domain, a long collagenous triple helical domain, and a carboxy-terminal NC1 domain (Figure 2). The N- and C-terminal regions serve to connect neighboring trimers. Like laminins, collagen IVs spontaneously aggregate into an extracellular matrix. There are six ($\alpha 1$ - $\alpha 6$) collagen IV chains, and these are arranged in head-to-head pairs, each using a common bifunctional promoter ($\alpha 1$ - $\alpha 2$, $\alpha 3$ - $\alpha 4$, and $\alpha 5$ - $\alpha 6$). In skeletal muscle, collagen IV($\alpha 1$)₂($\alpha 2$) is the major form of collagen IV in the extrasynaptic BL, while collagen IV ($\alpha 3$, $\alpha 4$, $\alpha 5$) and collagen IV($\alpha 5$)₂($\alpha 6$) are exclusively present at the NMJ (Sanes et al., 1990; Miner and Sanes, 1994; Fox et al., 2007) (Figure 1). Collagen IVs ($\alpha 3$ - $\alpha 6$) become expressed at the NMJ very late, on or after the third postnatal week, after the NMJ has taken on its adult form (Fox et al., 2007). There are human diseases associated with defective expression of (or autoimmune responses to) collagen IV($\alpha 3$, $\alpha 4$, and $\alpha 5$), including Goodpasture syndrome and Alport syndrome. These disorders result in kidney disease due to altered collagen IV expression in the renal glomerular basement membrane, but these diseases show no obvious neuromuscular phenotype (Miner, 2011).

Mice lacking collagen IV ($\alpha 5$) lack all synaptic collagen IVs, as collagen IV($\alpha 5$) is required in both collagen IV trimers found at the NMJ (Fox et al., 2007). Collagen IV($\alpha 5$)-deficient mice show no NMJ phenotype 3 weeks after birth, as expected since collagen IVs are not expressed until this age. By two months, however, these mice show fragmented pre- and postsynaptic specializations (Fox et al., 2007). In addition, they have NMJs with partially retracted or distended nerve terminals, sometimes leaving portions of postsynaptic AChR unopposed by the nerve, and have ring-like structures of neurofilament in some nerve terminals (Fox et al., 2007). These phenotypes are not apparent in mice lacking collagen IV ($\alpha 3$), which still make collagen IV ($\alpha 5$)₂($\alpha 6$), or in mice lacking collagen IV ($\alpha 6$), which still make collagen IV ($\alpha 3$, $\alpha 4$, $\alpha 5$) (Fox et al., 2007). Thus, there likely is some molecular compensation between different collagen IV trimers. Additional support for collagen IVs having roles in synaptic development comes from the finding that proteolyzed NC1 domains of certain collagen IVs induce presynaptic differentiation of cultured motor neurons (Fox et al., 2007). The NC1 domains of collagen IV ($\alpha 2$, $\alpha 3$, and $\alpha 6$) have such activity while the NC1 domains of collagen IV ($\alpha 1$, $\alpha 4$, and $\alpha 5$) do not. While others have certainly gone down blind alleys studying proteolytic fragments of collagens, these findings supplement the *in vivo* evidence showing that collagen IVs have roles in the maturation and the maintenance of NMJ.

Collagen XIII, a transmembrane collagenous trimer flanked by NC sequences (Hagg et al., 1998; Snellman et al., 2000), is expressed by skeletal muscle and may be cleaved and deposited in the synaptic ECM (Latvanlehto et al., 2010). At the NMJ, Collagen XIII is detectable at very low levels in the early postnatal period, with expression more apparent after two weeks of age (Latvanlehto et al., 2010). While collagen XIII is expressed in many tissues (Hagg et al., 2001; Sund et al., 2001), muscle-specific deletion leads to incomplete adhesion of the pre- and postsynaptic cell to the synaptic BL at the NMJ (Latvanlehto et al., 2010). Like laminin $\beta 2$ mutants (Noakes et al., 1995), collagen XIII-deficient mutants also show invasion of the synaptic cleft by the capping synaptic Schwann cell. Functionally, collagen XIII-deficient mice show slightly but significantly reduced miniature endplate potential (mEPP) amplitude, but they have dramatic reductions in mEPP frequency (Latvanlehto et al., 2010). These mice also have a deficit in the readily releasable pool,

indicating a presynaptic functional defect (Latvanlehto et al., 2010). These phenotypes become apparent in the adult animals, and animals develop tremors as they age.

The final collagen at the neuromuscular junction is ColQ, the collagenous subunit of acetylcholinesterase (AChE) (Figure 2) (Rotundo, 2003; Massoulie and Millard, 2009). AChE within the synaptic cleft degrades acetylcholine secreted by the nerve terminal after nerve excitation. AChE forms tetrameric, octameric, and dodecameric complexes of catalytic subunits in muscle cells. These bind to ColQ at the NMJ to make “asymmetric” AChE forms (Hall, 1973; Sanes and Hall, 1979; Krejci et al., 1997). Mice lacking ColQ fail to localize AChE at the NMJ (Feng et al., 1999; Bernard et al., 2011). NMJs still form, however, albeit with slightly aberrant shape, and animals are born and survive for at least several weeks, with 10–20% surviving for up to three months (Feng et al., 1999). This is a pretty remarkable result, as inhibition of AChE should be fatal (as certain insecticide and military nerve gas AChE inhibitors attest to). Compensatory mechanisms, perhaps mediated by the capping synaptic Schwann cell, appear to make up for lost ACh clearance in the ColQ mutant animals, allowing the mice to live for some period of time. Legay and colleagues have argued that ColQ also interacts with MuSK and that ColQ-deficient myotubes have altered postsynaptic organization via this interaction (Cartaud et al., 2004; Sigoillot et al., 2010). ColQ also interacts with perlecan. Mice lacking perlecan, like mice lacking ColQ, fail to express AChE at the neuromuscular junction, but these mice, unlike ColQ mutants, die at birth from respiratory failure (Arikawa-Hirasawa et al., 2002). Heparin, which mimics the heparin sulfate glycosaminoglycans on perlecan, can remove AChE from the NMJ (Torres and Inestrosa, 1983; Brandan and Inestrosa, 1984). These studies also support a role for perlecan in localizing AChE to the synapse. Perlecan is an abundant muscle ECM protein that can also interact with laminin, nidogen, fibronectin, and collagen IV in the ECM and dystroglycan and other receptors in the muscle membrane (Figure 2) (Sanes et al., 1986; Talts et al., 1999). By virtue of its heparan sulfate glycosaminoglycans, perlecan may also interact with growth factors, including FGFs and HB-GAM (Peng et al., 1998). Thus, perlecan, along with agrin, may serve to localize many trophic factors to the NMJ. It is conceivable that loss of synaptic AChE in ColQ- and perlecan-deficient mice are related to the development of a coordinated synaptic protein complex. Alternatively, interactions of ColQ-AChE with MuSK and other synaptic proteins may localize AChE, while interactions of ColQ-AChE with perlecan may stabilize ECM expression, or vice versa.

CONCLUDING REMARKS

Extracellular matrix proteins that reside within the synaptic cleft at the neuromuscular junction play essential roles in almost all aspects of synaptic development, including synaptic initiation, topography, ultrastructure, maturation, stability and transmission. While the NMJ serves as a model to understand the formation of other types of synapses, one compelling difference is that interneuronal synapses in the CNS, as well as the NMJs of invertebrates (see Brodie et al., Wlodarczyk et al, this issue), do not possess a synaptic basal lamina. Protein interacting motifs present at the NMJ, however, are present nonetheless at such synapses. Agrin can exist in a transmembrane form in neurons that can localize to CNS synapses (Burgess et al., 2000), laminin LG domains are present on CNS synaptic transmembrane proteins like neuroligins (Ushkaryov et al., 1992), which also interact with dystroglycan (Sugita et al., 2001). Integrins and dystroglycan are localized to certain classes of CNS synapses (Montanaro et al., 1995; Gerrow and El-Husseini, 2006). Neuroligins, synaptic neuroligin-binding proteins, contain non-catalytic domains of acetylcholinesterase (Ichtchenko et al., 1995), and the list goes on. Indeed, laminins containing laminin $\beta 2$ can be present at certain CNS synapses, albeit in a non-BL configuration (Egles et al., 2007). Thus, while the ECM may not be present in the same form as is found at the neuromuscular junction, it is likely that many of the same types of protein-protein or protein-glycan

interactions found at the NMJ will be present at synapses elsewhere in the nervous system. The difference primarily may lie in the context for such adhesive interactions and signaling, with cell-cell adhesion and signaling mechanisms driving CNS synapse formation and cell-ECM mechanisms predominating at the vertebrate NMJ.

Acknowledgments

The authors would like to thank Marybeth Camboni, Laura Martin, and the Editors for their very helpful comments. This work was funded in part by a grant from the National Institutes of Health R01AR049722 to PTM.

REFERENCES

- Adams ME, Kramarcy N, Krall SP, Rossi SG, Rotundo RL, Sealock R, Froehner SC. Absence of alpha-syntrophin leads to structurally aberrant neuromuscular synapses deficient in utrophin. *J Cell Biol.* 2000; 150:1385–1398. [PubMed: 10995443]
- Altiock N, Bessereau JL, Changeux JP. ErbB3 and ErbB2/neu mediate the effect of heregulin on acetylcholine receptor gene expression in muscle: differential expression at the endplate. *EMBO J.* 1995; 14:4258–4266. [PubMed: 7556067]
- Apel ED, Glass DJ, Moscoso LM, Yancopoulos GD, Sanes JR. Rapsyn is required for MuSK signaling and recruits synaptic components to a MuSK-containing scaffold. *Neuron.* 1997; 18:623–635. [PubMed: 9136771]
- Arber S, Caroni P. Thrombospondin-4, an extracellular matrix protein expressed in the developing and adult nervous system promotes neurite outgrowth. *The Journal of cell biology.* 1995; 131:1083–1094. [PubMed: 7490284]
- Arikawa-Hirasawa E, Rossi SG, Rotundo RL, Yamada Y. Absence of acetylcholinesterase at the neuromuscular junctions of perlecan-null mice. *Nat Neurosci.* 2002; 5:119–123. [PubMed: 11802174]
- Aumailley M, Battaglia C, Mayer U, Reinhardt D, Nischt R, Timpl R, Fox JW. Nidogen mediates the formation of ternary complexes of basement membrane components. *Kidney Int.* 1993; 43:7–12. [PubMed: 8433572]
- Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P, Engel J, Engvall E, Hohenester E, Jones JC, Kleinman HK, Marinkovich MP, Martin GR, Mayer U, Meneguzzi G, Miner JH, Miyazaki K, Patarroyo M, Paulsson M, Quaranta V, Sanes JR, Sasaki T, Sekiguchi K, Sorokin LM, Talts JF, Tryggvason K, Uitto J, Virtanen I, von der Mark K, Wewer UM, Yamada Y, Yurchenco PD. A simplified laminin nomenclature. *Matrix Biol.* 2005; 24:326–332. [PubMed: 15979864]
- Balice-Gordon RJ, Lichtman JW. In vivo visualization of the growth of pre- and postsynaptic elements of neuromuscular junctions in the mouse. *J Neurosci.* 1990; 10:894–908. [PubMed: 2156964]
- Barresi R, Campbell KP. Dystroglycan: from biosynthesis to pathogenesis of human disease. *J Cell Sci.* 2006; 119:199–207. [PubMed: 16410545]
- Bentzinger CF, Barzaghi P, Lin S, Ruegg MA. Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice. *Faseb J.* 2005; 19:934–942. [PubMed: 15923403]
- Bergamin E, Hallock PT, Burden SJ, Hubbard SR. The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization. *Mol Cell.* 2010; 39:100–109. [PubMed: 20603078]
- Bernard V, Girard E, Hrabovska A, Camp S, Taylor P, Plaud B, Krejci E. Distinct localization of collagen Q and PRiMA forms of acetylcholinesterase at the neuromuscular junction. *Mol Cell Neurosci.* 2011; 46:272–281. [PubMed: 20883790]
- Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. *Physiol Rev.* 2002; 82:291–329. [PubMed: 11917091]
- Borges LS, Yechikhov S, Lee YI, Rudell JB, Friese MB, Burden SJ, Ferns MJ. Identification of a motif in the acetylcholine receptor beta subunit whose phosphorylation regulates rapsyn association and postsynaptic receptor localization. *J Neurosci.* 2008; 28:11468–11476. [PubMed: 18987183]

- Bowe MA, Deyst KA, Leszyk JD, Fallon JR. Identification and purification of an agrin receptor from Torpedo postsynaptic membranes: a heteromeric complex related to the dystroglycans. *Neuron*. 1994; 12:1173–1180. [PubMed: 8185951]
- Brandan E, Inestrosa NC. Binding of the asymmetric forms of acetylcholinesterase to heparin. *The Biochemical journal*. 1984; 221:415–422. [PubMed: 6089739]
- Brandon EP, Lin W, D'Amour KA, Pizzo DP, Dominguez B, Sugiura Y, Thode S, Ko CP, Thal LJ, Gage FH, Lee KF. Aberrant patterning of neuromuscular synapses in choline acetyltransferase-deficient mice. *J Neurosci*. 2003; 23:539–549. [PubMed: 12533614]
- Bromann PA, Weiner JA, Apel ED, Lewis RM, Sanes JR. A putative ariadne-like E3 ubiquitin ligase (PAUL) that interacts with the muscle-specific kinase (MuSK). *Gene Expr Patterns*. 2004; 4:77–84. [PubMed: 14678832]
- Burden SJ. Synapse-specific gene expression. *Trends Genet*. 1993; 9:12–16. [PubMed: 8434411]
- Burden SJ, Sargent PB, McMahan UJ. Acetylcholine receptors in regenerating muscle accumulate at original synaptic sites in the absence of the nerve. *J Cell Biol*. 1979; 82:412–425. [PubMed: 479308]
- Burgess RW, Dickman DK, Nunez L, Glass DJ, Sanes JR. Mapping sites responsible for interactions of agrin with neurons. *J Neurochem*. 2002; 83:271–284. [PubMed: 12423238]
- Burgess RW, Nguyen QT, Son YJ, Lichtman JW, Sanes JR. Alternatively spliced isoforms of nerve- and muscle-derived agrin: their roles at the neuromuscular junction. *Neuron*. 1999; 23:33–44. [PubMed: 10402191]
- Burgess RW, Skarnes WC, Sanes JR. Agrin isoforms with distinct amino termini: differential expression, localization, and function. *J Cell Biol*. 2000; 151:41–52. [PubMed: 11018052]
- Burkin DJ, Gu M, Hodges BL, Campanelli JT, Kaufman SJ. A functional role for specific spliced variants of the alpha7beta1 integrin in acetylcholine receptor clustering. *J Cell Biol*. 1998; 143:1067–1075. [PubMed: 9817762]
- Burkin DJ, Kim JE, Gu M, Kaufman SJ. Laminin and alpha7beta1 integrin regulate agrin-induced clustering of acetylcholine receptors. *J Cell Sci*. 2000; 113(Pt 16):2877–2886. [PubMed: 10910772]
- Burkin DJ, Wallace GQ, Milner DJ, Chaney EJ, Mulligan JA, Kaufman SJ. Transgenic expression of {alpha}7{beta}1 integrin maintains muscle integrity, increases regenerative capacity, promotes hypertrophy, and reduces cardiomyopathy in dystrophic mice. *Am J Pathol*. 2005; 166:253–263. [PubMed: 15632017]
- Burkin DJ, Wallace GQ, Nicol KJ, Kaufman DJ, Kaufman SJ. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. *J Cell Biol*. 2001; 152:1207–1218. [PubMed: 11257121]
- Campanelli JT, Gayer GG, Scheller RH. Alternative RNA splicing that determines agrin activity regulates binding to heparin and alpha-dystroglycan. *Development*. 1996; 122:1663–1672. [PubMed: 8625852]
- Carlson SS, Valdez G, Sanes JR. Presynaptic calcium channels and alpha3-integrins are complexed with synaptic cleft laminins, cytoskeletal elements and active zone components. *J Neurochem*. 2010; 115:654–666. [PubMed: 20731762]
- Cartaud A, Strohlic L, Guerra M, Blanchard B, Lambergeon M, Krejci E, Cartaud J, Legay C. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction. *J Cell Biol*. 2004; 165:505–515. [PubMed: 15159418]
- Chandrasekharan K, Martin PT. Genetic defects in muscular dystrophy. *Methods Enzymol*. 2010; 479:291–322. [PubMed: 20816173]
- Chen F, Qian L, Yang ZH, Huang Y, Ngo ST, Ruan NJ, Wang J, Schneider C, Noakes PG, Ding YQ, Mei L, Luo ZG. Rapsyn interaction with calpain stabilizes AChR clusters at the neuromuscular junction. *Neuron*. 2007; 55:247–260. [PubMed: 17640526]
- Chen J, Billings SE, Nishimune H. Calcium channels link the muscle-derived synapse organizer laminin beta2 to Bassoon and CAST/Erc2 to organize presynaptic active zones. *J Neurosci*. 2011; 31:512–525. [PubMed: 21228161]
- Chesova T, Khan MA, Schubert SW, Gavin AC, Buchou T, Jacob G, Sticht H, Allende J, Boldyreff B, Brenner HR, Hashemolhosseini S. Casein kinase 2-dependent serine phosphorylation of MuSK

- regulates acetylcholine receptor aggregation at the neuromuscular junction. *Genes Dev.* 2006; 20:1800–1816. [PubMed: 16818610]
- Chiu AY, Ko J. A novel epitope of entactin is present at the mammalian neuromuscular junction. *J Neurosci.* 1994; 14:2809–2817. [PubMed: 7514212]
- Chiu AY, Sanes JR. Development of basal lamina in synaptic and extrasynaptic portions of embryonic rat muscle. *Dev Biol.* 1984; 103:456–467. [PubMed: 6373447]
- Cho SI, Ko J, Patton BL, Sanes JR, Chiu AY. Motor neurons and Schwann cells distinguish between synaptic and extrasynaptic isoforms of laminin. *J Neurobiol.* 1998; 37:339–358. [PubMed: 9828041]
- Chu GC, Moscoso LM, Sliwkowski MX, Merlie JP. Regulation of the acetylcholine receptor epsilon subunit gene by recombinant ARIA: an in vitro model for transynaptic gene regulation. *Neuron.* 1995; 14:329–339. [PubMed: 7857642]
- Cifuentes-Diaz C, Velasco E, Meunier FA, Goudou D, Belkadi L, Faille L, Murawsky M, Angaut-Petit D, Molgo J, Schachner M, Saga Y, Aizawa S, Rieger F. The peripheral nerve and the neuromuscular junction are affected in the tenascin-Cdeficient mouse. *Cellular and molecular biology.* 1998; 44:357–379. [PubMed: 9593587]
- Cohen I, Rimer M, Lomo T, McMahan UJ. Agrin-induced postsynaptic-like apparatus in skeletal muscle fibers in vivo. *Mol Cell Neurosci.* 1997; 9:237–253. [PubMed: 9268503]
- Cohen MW, Hoffstrom BG, DeSimone DW. Active zones on motor nerve terminals contain alpha 3beta 1 integrin. *J Neurosci.* 2000; 20:4912–4921. [PubMed: 10864949]
- Cohn RD, Henry MD, Michele DE, Barresi R, Saito F, Moore SA, Flanagan JD, Skwarchuk MW, Robbins ME, Mendell JR, Williamson RA, Campbell KP. Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. *Cell.* 2002; 110:639–648. [PubMed: 12230980]
- Cote PD, Moukhles H, Lindenbaum M, Carbonetto S. Chimaeric mice deficient in dystroglycans develop muscular dystrophy and have disrupted myoneural synapses. *Nat Genet.* 1999; 23:338–342. [PubMed: 10610181]
- DeChiara TM, Bowen DC, Valenzuela DM, Simmons MV, Poueymirou WT, Thomas S, Kinetz E, Compton DL, Rojas E, Park JS, Smith C, DiStefano PS, Glass DJ, Burden SJ, Yancopoulos GD. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. *Cell.* 1996; 85:501–512. [PubMed: 8653786]
- Deconinck AE, Potter AC, Tinsley JM, Wood SJ, Vater R, Young C, Metzinger L, Vincent A, Slater CR, Davies KE. Postsynaptic abnormalities at the neuromuscular junctions of utrophin-deficient mice. *J Cell Biol.* 1997; 136:883–894. [PubMed: 9049253]
- Deconinck N, Tinsley J, De Backer F, Fisher R, Kahn D, Phelps S, Davies K, Gillis JM. Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice. *Nat Med.* 1997; 3:1216–1221. [PubMed: 9359695]
- Denzer AJ, Schulthess T, Fauser C, Schumacher B, Kammerer RA, Engel J, Ruegg MA. Electron microscopic structure of agrin and mapping of its binding site in laminin-1. *Embo J.* 1998; 17:335–343. [PubMed: 9430625]
- Durbeej M, Campbell KP. Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. *Curr Opin Genet Dev.* 2002; 12:349–361. [PubMed: 12076680]
- Egles C, Claudepierre T, Manglapus MK, Champliand MF, Brunken WJ, Hunter DD. Laminins containing the beta2 chain modulate the precise organization of CNS synapses. *Molecular and cellular neurosciences.* 2007; 34:288–298. [PubMed: 17189701]
- Engel AG, Ohno K, Sine SM. Congenital myasthenic syndromes: recent advances. *Arch Neurol.* 1999; 56:163–167. [PubMed: 10025421]
- Engel AG, Shen XM, Sencen D, Sine SM. What have we learned from the congenital myasthenic syndromes. *J Mol Neurosci.* 2010; 40:143–153. [PubMed: 19688192]
- Engvall E, Earwicker D, Haaparanta T, Ruoslahti E, Sanes JR. Distribution and isolation of four laminin variants; tissue restricted distribution of heterotrimers assembled from five different subunits. *Cell Regul.* 1990; 1:731–740. [PubMed: 2099832]

- Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. *Cell*. 1991; 66:1121–1131. [PubMed: 1913804]
- Ervasti JM, Sonnemann KJ. Biology of the striated muscle dystrophin-glycoprotein complex. *Int Rev Cytol*. 2008; 265:191–225. [PubMed: 18275889]
- Escher P, Lacazette E, Courtet M, Blindenbacher A, Landmann L, Bezakova G, Lloyd KC, Mueller U, Brenner HR. Synapses form in skeletal muscles lacking neuregulin receptors. *Science*. 2005; 308:1920–1923. [PubMed: 15976301]
- Eusebio A, Oliveri F, Barzaghi P, Ruegg MA. Expression of mouse agrin in normal, denervated and dystrophic muscle. *Neuromuscul Disord*. 2003; 13:408–415. [PubMed: 12798796]
- Falls DL, Rosen KM, Corfas G, Lane WS, Fischbach GD. ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. *Cell*. 1993; 72:801–815. [PubMed: 8453670]
- Fambrough DM. Control of acetylcholine receptors in skeletal muscle. *Physiol Rev*. 1979; 59:165–227. [PubMed: 375254]
- Farrugia ME, Vincent A. Autoimmune mediated neuromuscular junction defects. *Curr Opin Neurol*. 2010; 23:489–495. [PubMed: 20651592]
- Feng G, Krejci E, Molgo J, Cunningham JM, Massoulié J, Sanes JR. Genetic analysis of collagen Q: roles in acetylcholinesterase and butyrylcholinesterase assembly and in synaptic structure and function. *J Cell Biol*. 1999; 144:1349–1360. [PubMed: 10087275]
- Finn AJ, Feng G, Pendergast AM. Postsynaptic requirement for Abl kinases in assembly of the neuromuscular junction. *Nat Neurosci*. 2003; 6:717–723. [PubMed: 12796783]
- Flanagan-Steet H, Fox MA, Meyer D, Sanes JR. Neuromuscular synapses can form in vivo by incorporation of initially aneural postsynaptic specializations. *Development*. 2005; 132:4471–4481. [PubMed: 16162647]
- Fox JW, Mayer U, Nischt R, Aumailley M, Reinhardt D, Wiedemann H, Mann K, Timpl R, Krieg T, Engel J, et al. Recombinant nidogen consists of three globular domains and mediates binding of laminin to collagen type IV. *EMBO J*. 1991; 10:3137–3146. [PubMed: 1717261]
- Fox MA, Ho MS, Smyth N, Sanes JR. A synaptic nidogen: developmental regulation and role of nidogen-2 at the neuromuscular junction. *Neural Dev*. 2008; 3:24. [PubMed: 18817539]
- Fox MA, Sanes JR, Borza DB, Eswarakumar VP, Fassler R, Hudson BG, John SW, Ninomiya Y, Pedchenko V, Pfaff SL, Rheault MN, Sado Y, Segal Y, Werle MJ, Umemori H. Distinct target-derived signals organize formation, maturation, and maintenance of motor nerve terminals. *Cell*. 2007; 129:179–193. [PubMed: 17418794]
- Frail DE, McLaughlin LL, Mudd J, Merlie JP. Identification of the mouse muscle 43,000-dalton acetylcholine receptor-associated protein (RAPsyn) by cDNA cloning. *J Biol Chem*. 1988; 263:15602–15607. [PubMed: 3170600]
- Fu AK, Ip FC, Fu WY, Cheung J, Wang JH, Yung WH, Ip NY. Aberrant motor axon projection, acetylcholine receptor clustering, and neurotransmission in cyclin-dependent kinase 5 null mice. *Proc Natl Acad Sci U S A*. 2005; 102:15224–15229. [PubMed: 16203963]
- Gassmann M, Lemke G. Neuregulins and neuregulin receptors in neural development. *Curr Opin Neurobiol*. 1997; 7:87–92. [PubMed: 9039794]
- Gautam M, Noakes PG, Moscoso L, Rupp F, Scheller RH, Merlie JP, Sanes JR. Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. *Cell*. 1996; 85:525–535. [PubMed: 8653788]
- Gautam M, Noakes PG, Mudd J, Nichol M, Chu GC, Sanes JR, Merlie JP. Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyndeficient mice. *Nature*. 1995; 377:232–236. [PubMed: 7675108]
- Gawlik K, Miyagoe-Suzuki Y, Ekblom P, Takeda S, Durbeek M. Laminin alpha1 chain reduces muscular dystrophy in laminin alpha2 chain deficient mice. *Hum Mol Genet*. 2004; 13:1775–1784. [PubMed: 15213105]
- Gerrow K, El-Husseini A. Cell adhesion molecules at the synapse. *Front Biosci*. 2006; 11:2400–2419. [PubMed: 16720322]
- Gesemann M, Brancaccio A, Schumacher B, Ruegg MA. Agrin is a high-affinity binding protein of dystroglycan in non-muscle tissue. *J Biol Chem*. 1998; 273:600–605. [PubMed: 9417121]

- Gesemann M, Cavalli V, Denzer AJ, Brancaccio A, Schumacher B, Ruegg MA. Alternative splicing of agrin alters its binding to heparin, dystroglycan, and the putative agrin receptor. *Neuron*. 1996; 16:755–767. [PubMed: 8607994]
- Gesemann M, Denzer AJ, Ruegg MA. Acetylcholine receptor-aggregating activity of agrin isoforms and mapping of the active site. *J Cell Biol*. 1995; 128:625–636. [PubMed: 7860635]
- Glass DJ, Bowen DC, Stitt TN, Radziejewski C, Bruno J, Ryan TE, Gies DR, Shah S, Mattsson K, Burden SJ, DiStefano PS, Valenzuela DM, DeChiara TM, Yancopoulos GD. Agrin acts via a MuSK receptor complex. *Cell*. 1996; 85:513–523. [PubMed: 8653787]
- Godfrey EW, Nitkin RM, Wallace BG, Rubin LL, McMahan UJ. Components of Torpedo electric organ and muscle that cause aggregation of acetylcholine receptors on cultured muscle cells. *J Cell Biol*. 1984; 99:615–627. [PubMed: 6746740]
- Goodearl AD, Yee AG, Sandrock AW Jr, Corfas G, Fischbach GD. ARIA is concentrated in the synaptic basal lamina of the developing chick neuromuscular junction. *J Cell Biol*. 1995; 130:1423–1434. [PubMed: 7559763]
- Grady RM, Merlie JP, Sanes JR. Subtle neuromuscular defects in utrophindeficient mice. *J Cell Biol*. 1997; 136:871–882. [PubMed: 9049252]
- Grady RM, Zhou H, Cunningham JM, Henry MD, Campbell KP, Sanes JR. Maturation and maintenance of the neuromuscular synapse: genetic evidence for roles of the dystrophin-glycoprotein complex. *Neuron*. 2000; 25:279–293. [PubMed: 10719885]
- Hagg P, Rehn M, Huhtala P, Vaisanen T, Tamminen M, Pihlajaniemi T. Type XIII collagen is identified as a plasma membrane protein. *J Biol Chem*. 1998; 273:15590–15597. [PubMed: 9624150]
- Hagg P, Vaisanen T, Tuomisto A, Rehn M, Tu H, Huhtala P, Eskelinen S, Pihlajaniemi T. Type XIII collagen: a novel cell adhesion component present in a range of cell-matrix adhesions and in the intercalated discs between cardiac muscle cells. *Matrix Biol*. 2001; 19:727–742. [PubMed: 11223332]
- Hall ZW. Multiple forms of acetylcholinesterase and their distribution in endplate and non-endplate regions of rat diaphragm muscle. *J Neurobiol*. 1973; 4:343–361. [PubMed: 4724813]
- Hallock PT, Xu CF, Park TJ, Neubert TA, Curran T, Burden SJ. Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L. *Genes Dev*. 2010; 24:2451–2461. [PubMed: 21041412]
- Han B, Fischbach GD. Processing of ARIA and release from isolated nerve terminals. *Philos Trans R Soc Lond B Biol Sci*. 1999; 354:411–416. [PubMed: 10212491]
- Hara Y, Balci-Hayta B, Yoshida-Moriguchi T, Kanagawa M, Beltran-Valero de Bernabe D, Gundesli H, Willer T, Satz JS, Crawford RW, Burden SJ, Kunz S, Oldstone MB, Accardi A, Talim B, Muntoni F, Topaloglu H, Dincer P, Campbell KP. A dystroglycan mutation associated with limb-girdle muscular dystrophy. *N Engl J Med*. 2011; 364:939–946. [PubMed: 21388311]
- Hayashi YK, Chou FL, Engvall E, Ogawa M, Matsuda C, Hirabayashi S, Yokochi K, Ziober BL, Kramer RH, Kaufman SJ, Ozawa E, Goto Y, Nonaka I, Tsukahara T, Wang JZ, Hoffman EP, Arahata K. Mutations in the integrin alpha7 gene cause congenital myopathy. *Nat Genet*. 1998; 19:94–97. [PubMed: 9590299]
- Herbst R, Avetisova E, Burden SJ. Restoration of synapse formation in Musk mutant mice expressing a Musk/Trk chimeric receptor. *Development*. 2002; 129:5449–5460. [PubMed: 12403715]
- Herbst R, Burden SJ. The juxtamembrane region of MuSK has a critical role in agrin-mediated signaling. *EMBO J*. 2000; 19:67–77. [PubMed: 10619845]
- Hezel M, de Groat WC, Galbiati F. Caveolin-3 promotes nicotinic acetylcholine receptor clustering and regulates neuromuscular junction activity. *Mol Biol Cell*. 2010; 21:302–310. [PubMed: 19940021]
- Hilgenberg LG, Su H, Gu H, O'Dowd DK, Smith MA. Alpha3Na⁺/K⁺-ATPase is a neuronal receptor for agrin. *Cell*. 2006; 125:359–369. [PubMed: 16630822]
- Hoch W, Ferns M, Campanelli JT, Hall ZW, Scheller RH. Developmental regulation of highly active alternatively spliced forms of agrin. *Neuron*. 1993; 11:479–490. [PubMed: 8398141]
- Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell*. 1987; 51:919–928. [PubMed: 3319190]

- Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD, et al. Identification of heregulin, a specific activator of p185erbB2. *Science*. 1992; 256:1205–1210. [PubMed: 1350381]
- Hoyte K, Kang C, Martin PT. Definition of pre- and postsynaptic forms of the CT carbohydrate antigen at the neuromuscular junction: ubiquitous expression of the CT antigens and the CT GalNAc transferase in mouse tissues. *Brain Res Mol Brain Res*. 2002; 109:146–160. [PubMed: 12531524]
- Hughes BW, Kusner LL, Kaminski HJ. Molecular architecture of the neuromuscular junction. *Muscle Nerve*. 2006; 33:445–461. [PubMed: 16228970]
- Hunter DD, Porter BE, Bullock JW, Adams SP, Merlie JP, Sanes JR. Primary sequence of a motor neuron-selective adhesive site in the synaptic basal lamina protein S-laminin. *Cell*. 1989; 59:905–913. [PubMed: 2590946]
- Huze C, Bauche S, Richard P, Chevessier F, Goillot E, Gaudon K, Ben Ammar A, Chaboud A, Grosjean I, Lecuyer HA, Bernard V, Rouche A, Alexandri N, Kuntzer T, Fardeau M, Fournier E, Brancaccio A, Ruegg MA, Koenig J, Eymard B, Schaeffer L, Hantai D. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. *Am J Hum Genet*. 2009; 85:155–167. [PubMed: 19631309]
- Ibraghimov-Beskrovnaia O, Milatovich A, Ozcelik T, Yang B, Koepnick K, Francke U, Campbell KP. Human dystroglycan: skeletal muscle cDNA, genomic structure, origin of tissue specific isoforms and chromosomal localization. *Hum Mol Genet*. 1993; 2:1651–1657. [PubMed: 8268918]
- Ichtchenko K, Hata Y, Nguyen T, Ullrich B, Missler M, Moomaw C, Sudhof TC. Neuroligin 1: a splice site-specific ligand for beta-neurexins. *Cell*. 1995; 81:435–443. [PubMed: 7736595]
- Inoue A, Setoguchi K, Matsubara Y, Okada K, Sato N, Iwakura Y, Higuchi O, Yamanashi Y. Dok-7 activates the muscle receptor kinase MuSK and shapes synapse formation. *Sci Signal*. 2009; 2:ra7. [PubMed: 19244212]
- Jaworski A, Burden SJ. Neuromuscular synapse formation in mice lacking motor neuron- and skeletal muscle-derived Neuregulin-1. *J Neurosci*. 2006; 26:655–661. [PubMed: 16407563]
- Jennings CG, Dyer SM, Burden SJ. Muscle-specific trk-related receptor with a kringle domain defines a distinct class of receptor tyrosine kinases. *Proc Natl Acad Sci U S A*. 1993; 90:2895–2899. [PubMed: 8385349]
- Jenniskens GJ, Oosterhof A, Brandwijk R, Veerkamp JH, van Kuppevelt TH. Heparan sulfate heterogeneity in skeletal muscle basal lamina: demonstration by phage display-derived antibodies. *J Neurosci*. 2000; 20:4099–4111. [PubMed: 10818145]
- Jo SA, Zhu X, Marchionni MA, Burden SJ. Neuregulins are concentrated at nervemuscle synapses and activate ACh-receptor gene expression. *Nature*. 1995; 373:158–161. [PubMed: 7816098]
- Jones G, Meier T, Lichtsteiner M, Witzemann V, Sakmann B, Brenner HR. Induction by agrin of ectopic and functional postsynaptic-like membrane in innervated muscle. *Proc Natl Acad Sci U S A*. 1997; 94:2654–2659. [PubMed: 9122251]
- Kadler KE, Baldock C, Bella J, Boot-Handford RP. Collagens at a glance. *Journal of cell science*. 2007; 120:1955–1958. [PubMed: 17550969]
- Kim ML, Chandrasekharan K, Glass M, Shi S, Stahl MC, Kaspar B, Stanley P, Martin PT. O-fucosylation of muscle agrin determines its ability to cluster acetylcholine receptors. *Mol Cell Neurosci*. 2008; 39:452–464. [PubMed: 18775496]
- Kim N, Burden SJ. MuSK controls where motor axons grow and form synapses. *Nat Neurosci*. 2008; 11:19–27. [PubMed: 18084289]
- Kim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM, Huang JH, Hubbard SR, Dustin ML, Burden SJ. Lrp4 is a receptor for Agrin and forms a complex with MuSK. *Cell*. 2008; 135:334–342. [PubMed: 18848351]
- Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. *Cell*. 1987; 50:509–517. [PubMed: 3607877]
- Korkut C, Budnik V. WNTs tune up the neuromuscular junction. *Nat Rev Neurosci*. 2009; 10:627–634. [PubMed: 19693027]

- Krejci E, Thomine S, Boschetti N, Legay C, Sketelj J, Massoulie J. The mammalian gene of acetylcholinesterase-associated collagen. *J Biol Chem.* 1997; 272:22840–22847. [PubMed: 9278446]
- Kummer TT, Misgeld T, Sanes JR. Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost. *Curr Opin Neurobiol.* 2006; 16:74–82. [PubMed: 16386415]
- Lacazette E, Le Calvez S, Gajendran N, Brenner HR. A novel pathway for MuSK to induce key genes in neuromuscular synapse formation. *J Cell Biol.* 2003; 161:727–736. [PubMed: 12756238]
- Lampe AK, Bushby KM. Collagen VI related muscle disorders. *J Med Genet.* 2005; 42:673–685. [PubMed: 16141002]
- LaRochelle WJ, Froehner SC. Determination of the tissue distributions and relative concentrations of the postsynaptic 43-kDa protein and the acetylcholine receptor in Torpedo. *J Biol Chem.* 1986; 261:5270–5274. [PubMed: 3514614]
- Latvanlehto A, Fox MA, Sormunen R, Tu H, Oikarainen T, Koski A, Naumenko N, Shakirzyanova A, Kallio M, Ilves M, Giniatullin R, Sanes JR, Pihlajaniemi T. Muscle-derived collagen XIII regulates maturation of the skeletal neuromuscular junction. *J Neurosci.* 2010; 30:12230–12241. [PubMed: 20844119]
- Lee CY, Tseng LF, Chin TH. Influence of denervation on the localization of neurotoxins from clapid venom in rat diaphragm. *Nature.* 1967; 215:1177–1178. [PubMed: 4294063]
- Lemke G. Neuregulin-1 and myelination. *Sci STKE.* 2006; 2006:pe11. [PubMed: 16522871]
- Lemke GE, Brookes JP. Identification and purification of glial growth factor. *J Neurosci.* 1984; 4:75–83. [PubMed: 6693948]
- Letinsky MS, Fischbeck KH, McMahan UJ. Precision of reinnervation of original postsynaptic sites in frog muscle after a nerve crush. *J Neurocytol.* 1976; 5:691–718. [PubMed: 1087337]
- Leu M, Bellmunt E, Schwander M, Farinas I, Brenner HR, Muller U. Erbb2 regulates neuromuscular synapse formation and is essential for muscle spindle development. *Development.* 2003; 130:2291–2301. [PubMed: 12702645]
- Lin W, Burgess RW, Dominguez B, Pfaff SL, Sanes JR, Lee KF. Distinct roles of nerve and muscle in postsynaptic differentiation of the neuromuscular synapse. *Nature.* 2001; 410:1057–1064. [PubMed: 11323662]
- Lin W, Dominguez B, Yang J, Aryal P, Brandon EP, Gage FH, Lee KF. Neurotransmitter acetylcholine negatively regulates neuromuscular synapse formation by a Cdk5-dependent mechanism. *Neuron.* 2005; 46:569–579. [PubMed: 15944126]
- Lin W, Sanchez HB, Deerinck T, Morris JK, Ellisman M, Lee KF. Aberrant development of motor axons and neuromuscular synapses in erbB2-deficient mice. *Proc Natl Acad Sci U S A.* 2000; 97:1299–1304. [PubMed: 10655525]
- Linnoila J, Wang Y, Yao Y, Wang ZZ. A mammalian homolog of *Drosophila* tumorous imaginal discs, Tid1, mediates agrin signaling at the neuromuscular junction. *Neuron.* 2008; 60:625–641. [PubMed: 19038220]
- Love DR, Hill DF, Dickson G, Spurr NK, Byth BC, Marsden RF, Walsh FS, Edwards YH, Davies KE. An autosomal transcript in skeletal muscle with homology to dystrophin. *Nature.* 1989; 339:55–58. [PubMed: 2541343]
- Lu Z, Je HS, Young P, Gross J, Lu B, Feng G. Regulation of synaptic growth and maturation by a synapse-associated E3 ubiquitin ligase at the neuromuscular junction. *J Cell Biol.* 2007; 177:1077–1089. [PubMed: 17576800]
- Luo ZG, Je HS, Wang Q, Yang F, Dobbins GC, Yang ZH, Xiong WC, Lu B, Mei L. Implication of geranylgeranyltransferase I in synapse formation. *Neuron.* 2003; 40:703–717. [PubMed: 14622576]
- Luo ZG, Wang Q, Zhou JZ, Wang J, Luo Z, Liu M, He X, Wynshaw-Boris A, Xiong WC, Lu B, Mei L. Regulation of AChR clustering by Dishevelled interacting with MuSK and PAK1. *Neuron.* 2002; 35:489–505. [PubMed: 12165471]
- Madhavan R, Zhao XT, Ruegg MA, Peng HB. Tyrosine phosphatase regulation of MuSK-dependent acetylcholine receptor clustering. *Mol Cell Neurosci.* 2005; 28:403–416. [PubMed: 15737732]
- Magill-Solc C, McMahan UJ. Agrin-like molecules in motor neurons. *J Physiol (Paris).* 1990; 84:78–81. [PubMed: 2193148]

- Magill-Solc C, McMahan UJ. Synthesis and transport of agrin-like molecules in motor neurons. *J Exp Biol.* 1990; 153:1–10. [PubMed: 2177765]
- Marchionni MA, Goodearl AD, Chen MS, Birmingham-McDonogh O, Kirk C, Hendricks M, Danehy F, Misumi D, Sudhalter J, Kobayashi K, et al. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. *Nature.* 1993; 362:312–318. [PubMed: 8096067]
- Marshall LM, Sanes JR, McMahan UJ. Reinnervation of original synaptic sites on muscle fiber basement membrane after disruption of the muscle cells. *Proc Natl Acad Sci U S A.* 1977; 74:3073–3077. [PubMed: 302451]
- Martin PT. Dystroglycan glycosylation and its role in matrix binding in skeletal muscle. *Glycobiology.* 2003; 13:55R–66R.
- Martin PT. Mechanisms of Disease: congenital muscular dystrophies-glycosylation takes center stage. *Nat Clin Pract Neurol.* 2006; 2:222–230. [PubMed: 16932553]
- Martin PT, Ettinger AJ, Sanes JR. A synaptic localization domain in the synaptic cleft protein laminin beta 2 (s-laminin). *Science.* 1995; 269:413–416. [PubMed: 7618109]
- Martin PT, Kaufman SJ, Kramer RH, Sanes JR. Synaptic integrins in developing, adult, and mutant muscle: selective association of alpha1, alpha7A, and alpha7B integrins with the neuromuscular junction. *Dev Biol.* 1996; 174:125–139. [PubMed: 8626012]
- Martin PT, Sanes JR. Integrins mediate adhesion to agrin and modulate agrin signaling. *Development.* 1997; 124:3909–3917. [PubMed: 9367446]
- Martin PT, Scott LJ, Porter BE, Sanes JR. Distinct structures and functions of related pre- and postsynaptic carbohydrates at the mammalian neuromuscular junction. *Mol Cell Neurosci.* 1999; 13:105–118. [PubMed: 10192769]
- Martin PT, Xu R, Rodino-Klapac LR, Oglesbay E, Camboni M, Montgomery CL, Shontz K, Chicoine LG, Clark KR, Sahenk Z, Mendell JR, Janssen PM. Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. *Am J Physiol Cell Physiol.* 2009; 296:C476–C488. [PubMed: 19109526]
- Maselli RA, Ng JJ, Anderson JA, Cagney O, Arredondo J, Williams C, Wessel HB, Abdel-Hamid H, Wollmann RL. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. *J Med Genet.* 2009; 46:203–208. [PubMed: 19251977]
- Massoulié J, Millard CB. Cholinesterases and the basal lamina at vertebrate neuromuscular junctions. *Curr Opin Pharmacol.* 2009; 9:316–325. [PubMed: 19423392]
- Matsumura K, Ervasti JM, Ohlendieck K, Kahl SD, Campbell KP. Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. *Nature.* 1992; 360:588–591. [PubMed: 1461282]
- May P, Woldt E, Matz RL, Boucher P. The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions. *Ann Med.* 2007; 39:219–228. [PubMed: 17457719]
- Mayer U, Saher G, Fassler R, Bornemann A, Echtermeyer F, von der Mark H, Miosge N, Poschl E, von der Mark K. Absence of integrin alpha 7 causes a novel form of muscular dystrophy. *Nat Genet.* 1997; 17:318–323. [PubMed: 9354797]
- McMahan UJ, Sanes JR, Marshall LM. Cholinesterase is associated with the basal lamina at the neuromuscular junction. *Nature.* 1978; 271:172–174. [PubMed: 622157]
- Meier T, Marangi PA, Moll J, Hauser DM, Brenner HR, Ruegg MA. A minigene of neural agrin encoding the laminin-binding and acetylcholine receptor aggregating domains is sufficient to induce postsynaptic differentiation in muscle fibres. *Eur J Neurosci.* 1998; 10:3141–3152. [PubMed: 9786208]
- Meier T, Masciulli F, Moore C, Schoumacher F, Eppenberger U, Denzer AJ, Jones G, Brenner HR. Agrin can mediate acetylcholine receptor gene expression in muscle by aggregation of muscle-derived neuregulins. *J Cell Biol.* 1998; 141:715–726. [PubMed: 9566971]
- Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, Dollar J, Nishino I, Kelley RI, Somer H, Straub V, Mathews KD, Moore SA, Campbell KP. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. *Nature.* 2002; 418:417–422. [PubMed: 12140558]
- Michele DE, Campbell KP. Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. *J Biol Chem.* 2003; 278:15457–15460. [PubMed: 12556455]

- Miner JH. Glomerular basement membrane composition and the filtration barrier. *Pediatr Nephrol.* 2011
- Miner JH, Cunningham J, Sanes JR. Roles for laminin in embryogenesis: exencephaly, syndactyly, and placentopathy in mice lacking the laminin alpha5 chain. *J Cell Biol.* 1998; 143:1713–1723. [PubMed: 9852162]
- Miner JH, Go G, Cunningham J, Patton BL, Jarad G. Transgenic isolation of skeletal muscle and kidney defects in laminin beta2 mutant mice: implications for Pierson syndrome. *Development.* 2006; 133:967–975. [PubMed: 16452099]
- Miner JH, Sanes JR. Collagen IV alpha 3, alpha 4, and alpha 5 chains in rodent basal laminae: sequence, distribution, association with laminins, and developmental switches. *J Cell Biol.* 1994; 127:879–891. [PubMed: 7962065]
- Misgeld T, Kummer TT, Lichtman JW, Sanes JR. Agrin promotes synaptic differentiation by counteracting an inhibitory effect of neurotransmitter. *Proc Natl Acad Sci U S A.* 2005; 102:11088–11093. [PubMed: 16043708]
- Mittaud P, Camilleri AA, Willmann R, Erb-Vogtli S, Burden SJ, Fuhrer C. A single pulse of agrin triggers a pathway that acts to cluster acetylcholine receptors. *Mol Cell Biol.* 2004; 24:7841–7854. [PubMed: 15340048]
- Moll J, Barzaghi P, Lin S, Bezakova G, Lochmuller H, Engvall E, Muller U, Ruegg MA. An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. *Nature.* 2001; 413:302–307. [PubMed: 11565031]
- Montanaro F, Carbonetto S, Campbell KP, Lindenbaum M. Dystroglycan expression in the wild type and mdx mouse neural retina: synaptic colocalization with dystrophin, dystrophin-related protein but not laminin. *J Neurosci Res.* 1995; 42:528–538. [PubMed: 8568939]
- Moscoso LM, Chu GC, Gautam M, Noakes PG, Merlie JP, Sanes JR. Synapse-associated expression of an acetylcholine receptor-inducing protein, ARIA/hergulin, and its putative receptors, ErbB2 and ErbB3, in developing mammalian muscle. *Dev Biol.* 1995; 172:158–169. [PubMed: 7589796]
- Moscoso LM, Cremer H, Sanes JR. Organization and reorganization of neuromuscular junctions in mice lacking neural cell adhesion molecule, tenascin-C, or fibroblast growth factor-5. *The Journal of neuroscience : the official journal of the Society for Neuroscience.* 1998; 18:1465–1477. [PubMed: 9454855]
- Moscoso LM, Merlie JP, Sanes JR. N-CAM, 43K-rapsyn, and S-laminin mRNAs are concentrated at synaptic sites in muscle fibers. *Mol Cell Neurosci.* 1995; 6:80–89. [PubMed: 7599960]
- Nguyen HH, Jayasinha V, Xia B, Hoyte K, Martin PT. Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. *Proc Natl Acad Sci U S A.* 2002; 99:5616–5621. [PubMed: 11960016]
- Nishimune H, Sanes JR, Carlson SS. A synaptic laminin-calcium channel interaction organizes active zones in motor nerve terminals. *Nature.* 2004; 432:580–587. [PubMed: 15577901]
- Nishimune H, Valdez G, Jarad G, Moulson CL, Muller U, Miner JH, Sanes JR. Laminins promote postsynaptic maturation by an autocrine mechanism at the neuromuscular junction. *J Cell Biol.* 2008; 182:1201–1215. [PubMed: 18794334]
- Nitkin RM, Smith MA, Magill C, Fallon JR, Yao YM, Wallace BG, McMahan UJ. Identification of agrin, a synaptic organizing protein from Torpedo electric organ. *J Cell Biol.* 1987; 105:2471–2478. [PubMed: 2826489]
- Noakes PG, Gautam M, Mudd J, Sanes JR, Merlie JP. Aberrant differentiation of neuromuscular junctions in mice lacking s-laminin/laminin beta 2. *Nature.* 1995; 374:258–262. [PubMed: 7885444]
- Ohlendieck K, Ervasti JM, Matsumura K, Kahl SD, Leveille CJ, Campbell KP. Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle. *Neuron.* 1991; 7:499–508. [PubMed: 1654951]
- Okada K, Inoue A, Okada M, Murata Y, Kakuta S, Jigami T, Kubo S, Shiraishi H, Eguchi K, Motomura M, Akiyama T, Iwakura Y, Higuchi O, Yamanashi Y. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. *Science.* 2006; 312:1802–1805. [PubMed: 16794080]


- Panzer JA, Gibbs SM, Dosch R, Wagner D, Mullins MC, Granato M, Balice-Gordon RJ. Neuromuscular synaptogenesis in wild-type and mutant zebrafish. *Dev Biol.* 2005; 285:340–357. [PubMed: 16102744]
- Patton BL, Chiu AY, Sanes JR. Synaptic laminin prevents glial entry into the synaptic cleft. *Nature.* 1998; 393:698–701. [PubMed: 9641682]
- Patton BL, Connoll AM, Martin PT, Cunningham JM, Mehta S, Pestronk A, Miner JH, Sanes JR. Distribution of ten laminin chains in dystrophic and regenerating muscles. *Neuromuscul Disord.* 1999; 9:423–433. [PubMed: 10545049]
- Patton BL, Cunningham JM, Thyboll J, Kortessmaa J, Westerblad H, Edstrom L, Tryggvason K, Sanes JR. Properly formed but improperly localized synaptic specializations in the absence of laminin alpha4. *Nat Neurosci.* 2001; 4:597–604. [PubMed: 11369940]
- Patton BL, Miner JH, Chiu AY, Sanes JR. Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice. *J Cell Biol.* 1997; 139:1507–1521. [PubMed: 9396756]
- Peng HB, Ali AA, Daggett DF, Rauvala H, Hassell JR, Smalheiser NR. The relationship between perlecan and dystroglycan and its implication in the formation of the neuromuscular junction. *Cell Adhes Commun.* 1998; 5:475–489. [PubMed: 9791728]
- Peters MF, Adams ME, Froehner SC. Differential association of syntrophin pairs with the dystrophin complex. *J Cell Biol.* 1997; 138:81–93. [PubMed: 9214383]
- Peters MF, Sadoulet-Puccio HM, Grady MR, Kramarcy NR, Kunkel LM, Sanes JR, Sealock R, Froehner SC. Differential membrane localization and intermolecular associations of alpha-dystrobrevin isoforms in skeletal muscle. *J Cell Biol.* 1998; 142:1269–1278. [PubMed: 9732287]
- Ponomareva ON, Ma H, Vock VM, Ellerton EL, Moody SE, Dakour R, Chodosh LA, Rimer M. Defective neuromuscular synaptogenesis in mice expressing constitutively active ErbB2 in skeletal muscle fibers. *Mol Cell Neurosci.* 2006; 31:334–345. [PubMed: 16278083]
- Poschl E, Mayer U, Stetefeld J, Baumgartner R, Holak TA, Huber R, Timpl R. Site-directed mutagenesis and structural interpretation of the nidogen binding site of the laminin gamma1 chain. *EMBO J.* 1996; 15:5154–5159. [PubMed: 8895559]
- Rafael JA, Tinsley JM, Potter AC, Deconinck AE, Davies KE. Skeletal musclespecific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. *Nat Genet.* 1998; 19:79–82. [PubMed: 9590295]
- Reinhardt D, Mann K, Nischt R, Fox JW, Chu ML, Krieg T, Timpl R. Mapping of nidogen binding sites for collagen type IV, heparan sulfate proteoglycan, and zinc. *J Biol Chem.* 1993; 268:10881–10887. [PubMed: 8496153]
- Rimer M, Cohen I, Lomo T, Burden SJ, McMahan UJ. Neuregulins and erbB receptors at neuromuscular junctions and at agrin-induced postsynaptic-like apparatus in skeletal muscle. *Mol Cell Neurosci.* 1998; 12:1–15. [PubMed: 9770336]
- Rooney JE, Gurpur PB, Burkin DJ. Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. *Proc Natl Acad Sci U S A.* 2009; 106:7991–7996. [PubMed: 19416897]
- Rooney JE, Gurpur PB, Yablonka-Reuveni Z, Burkin DJ. Laminin-111 restores regenerative capacity in a mouse model for alpha7 integrin congenital myopathy. *Am J Pathol.* 2009; 174:256–264. [PubMed: 19074617]
- Rotundo RL. Expression and localization of acetylcholinesterase at the neuromuscular junction. *J Neurocytol.* 2003; 32:743–766. [PubMed: 15034265]
- Ruegg MA, Tsim KW, Horton SE, Kroger S, Escher G, Gensch EM, McMahan UJ. The agrin gene codes for a family of basal lamina proteins that differ in function and distribution. *Neuron.* 1992; 8:691–699. [PubMed: 1314621]
- Ruggiu M, Herbst R, Kim N, Jevsek M, Fak JJ, Mann MA, Fischbach G, Burden SJ, Darnell RB. Rescuing Z+ agrin splicing in Nova null mice restores synapse formation and unmask a physiologic defect in motor neuron firing. *Proc Natl Acad Sci U S A.* 2009; 106:3513–3518. [PubMed: 19221030]
- Rupp F, Payan DG, Magill-Solc C, Cowan DM, Scheller RH. Structure and expression of a rat agrin. *Neuron.* 1991; 6:811–823. [PubMed: 1851019]

- Sadasivam G, Willmann R, Lin S, Erb-Vogtli S, Kong XC, Ruegg MA, Fuhrer C. Src-family kinases stabilize the neuromuscular synapse in vivo via protein interactions, phosphorylation, and cytoskeletal linkage of acetylcholine receptors. *J Neurosci*. 2005; 25:10479–10493. [PubMed: 16280586]
- Sandrock AW Jr, Dryer SE, Rosen KM, Gozani SN, Kramer R, Theill LE, Fischbach GD. Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo. *Science*. 1997; 276:599–603. [PubMed: 9110980]
- Sandrock AW Jr, Goodearl AD, Yin QW, Chang D, Fischbach GD. ARIA is concentrated in nerve terminals at neuromuscular junctions and at other synapses. *J Neurosci*. 1995; 15:6124–6136. [PubMed: 7666195]
- Sanes JR. The basement membrane/basal lamina of skeletal muscle. *J Biol Chem*. 2003; 278:12601–12604. [PubMed: 12556454]
- Sanes JR, Apel ED, Burgess RW, Emerson RB, Feng G, Gautam M, Glass D, Grady RM, Krejci E, Lichtman JW, Lu JT, Massoulie J, Miner JH, Moscoso LM, Nguyen Q, Nichol M, Noakes PG, Patton BL, Son YJ, Yancopoulos GD, Zhou H. Development of the neuromuscular junction: genetic analysis in mice. *J Physiol Paris*. 1998; 92:167–172. [PubMed: 9789802]
- Sanes JR, Engvall E, Butkowski R, Hunter DD. Molecular heterogeneity of basal laminae: isoforms of laminin and collagen IV at the neuromuscular junction and elsewhere. *J Cell Biol*. 1990; 111:1685–1699. [PubMed: 2211832]
- Sanes JR, Hall ZW. Antibodies that bind specifically to synaptic sites on muscle fiber basal lamina. *J Cell Biol*. 1979; 83:357–370. [PubMed: 91619]
- Sanes JR, Lichtman JW. Development of the vertebrate neuromuscular junction. *Annu Rev Neurosci*. 1999; 22:389–442. [PubMed: 10202544]
- Sanes JR, Lichtman JW. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. *Nat Rev Neurosci*. 2001; 2:791–805. [PubMed: 11715056]
- Sanes JR, Marshall LM, McMahan UJ. Reinnervation of muscle fiber basal lamina after removal of myofibers. Differentiation of regenerating axons at original synaptic sites. *J Cell Biol*. 1978; 78:176–198. [PubMed: 307554]
- Sanes JR, Schachner M, Covault J. Expression of several adhesive macromolecules (N-CAM, L1, J1, NILE, uvomorulin, laminin, fibronectin, and a heparan sulfate proteoglycan) in embryonic, adult, and denervated adult skeletal muscle. *J Cell Biol*. 1986; 102:420–431. [PubMed: 3511069]
- Sann SB, Xu L, Nishimune H, Sanes JR, Spitzer NC. Neurite outgrowth and in vivo sensory innervation mediated by a Ca(V)2.2-laminin beta 2 stop signal. *J Neurosci*. 2008; 28:2366–2374. [PubMed: 18322083]
- Schaeffer L, de Kerchove d'Exaerde A, Changeux JP. Targeting transcription to the neuromuscular synapse. *Neuron*. 2001; 31:15–22. [PubMed: 11498047]
- Schwander M, Leu M, Stumm M, Dorchie OM, Ruegg UT, Schittny J, Muller U. Beta1 integrins regulate myoblast fusion and sarcomere assembly. *Dev Cell*. 2003; 4:673–685. [PubMed: 12737803]
- Schwander M, Shirasaki R, Pfaff SL, Muller U. Beta1 integrins in muscle, but not in motor neurons, are required for skeletal muscle innervation. *J Neurosci*. 2004; 24:8181–8191. [PubMed: 15371519]
- Scotton P, Bleckmann D, Stebler M, Sciandra F, Brancaccio A, Meier T, Stetefeld J, Ruegg MA. Activation of muscle-specific receptor tyrosine kinase and binding to dystroglycan are regulated by alternative mRNA splicing of agrin. *J Biol Chem*. 2006; 281:36835–36845. [PubMed: 17012237]
- Sealock R, Wray BE, Froehner SC. Ultrastructural localization of the Mr 43,000 protein and the acetylcholine receptor in Torpedo postsynaptic membranes using monoclonal antibodies. *J Cell Biol*. 1984; 98:2239–2244. [PubMed: 6725413]
- Sigoillot SM, Bourgeois F, Lambergeon M, Strohlich L, Legay C. ColQ controls postsynaptic differentiation at the neuromuscular junction. *J Neurosci*. 2010; 30:13–23. [PubMed: 20053883]
- Smith CL, Mittaud P, Prescott ED, Fuhrer C, Burden SJ. Src, Fyn, and Yes are not required for neuromuscular synapse formation but are necessary for stabilization of agrin-induced clusters of acetylcholine receptors. *J Neurosci*. 2001; 21:3151–3160. [PubMed: 11312300]

- Snellman A, Keranen MR, Hagg PO, Lamberg A, Hiltunen JK, Kivirikko KI, Pihlajaniemi T. Type XIII collagen forms homotrimers with three triple helical collagenous domains and its association into disulfide-bonded trimers is enhanced by prolyl 4-hydroxylase. *J Biol Chem.* 2000; 275:8936–8944. [PubMed: 10722741]
- Sobel A, Heidmann T, Changeux JP. [Purification of a protein binding quinacrine and histrionicotoxin from membrane fragments rich in cholinergic receptors in *Torpedo marmorata*]. *C R Acad Sci Hebd Seances Acad Sci D.* 1977; 285:1255–1258. [PubMed: 413664]
- Son YJ, Scranton TW, Sunderland WJ, Baek SJ, Miner JH, Sanes JR, Carlson SS. The synaptic vesicle protein SV2 is complexed with an alpha5-containing laminin on the nerve terminal surface. *J Biol Chem.* 2000; 275:451–460. [PubMed: 10617638]
- Song WK, Wang W, Foster RF, Bielser DA, Kaufman SJ. H36-alpha 7 is a novel integrin alpha chain that is developmentally regulated during skeletal myogenesis. *J Cell Biol.* 1992; 117:643–657. [PubMed: 1315319]
- Sugita S, Saito F, Tang J, Satz J, Campbell K, Sudhof TC. A stoichiometric complex of neuexins and dystroglycan in brain. *J Cell Biol.* 2001; 154:435–445. [PubMed: 11470830]
- Sund M, Vaisanen T, Kaukinen S, Ilves M, Tu H, Autio-Harmanen H, Rauvala H, Pihlajaniemi T. Distinct expression of type XIII collagen in neuronal structures and other tissues during mouse development. *Matrix Biol.* 2001; 20:215–231. [PubMed: 11470398]
- Sunesen M, Changeux JP. Transcription in neuromuscular junction formation: who turns on whom? *J Neurocytol.* 2003; 32:677–684. [PubMed: 15034260]
- Talts JF, Andac Z, Gohring W, Brancaccio A, Timpl R. Binding of the G domains of laminin alpha 1 and alpha 2 chains and perlecan to heparin, sulfatides, alphadystroglycan and several extracellular matrix proteins. *Embo J.* 1999; 18:863–870. [PubMed: 10022829]
- Talts JF, Sasaki T, Miosge N, Gohring W, Mann K, Mayne R, Timpl R. Structural and functional analysis of the recombinant G domain of the laminin alpha 4 chain and its proteolytic processing in tissues. *J Biol Chem.* 2000; 275:35192–35199. [PubMed: 10934193]
- Tang H, Macpherson P, Argetsinger LS, Cieslak D, Suhr ST, Carter-Su C, Goldman D. CaM kinase II-dependent phosphorylation of myogenin contributes to activity-dependent suppression of nAChR gene expression in developing rat myotubes. *Cellular signalling.* 2004; 16:551–563. [PubMed: 14751541]
- Tang H, Macpherson P, Marvin M, Meadows E, Klein WH, Yang XJ, Goldman D. A histone deacetylase 4/myogenin positive feedback loop coordinates denervation-dependent gene induction and suppression. *Mol Biol Cell.* 2009; 20:1120–1131. [PubMed: 19109424]
- Tang H, Veldman MB, Goldman D. Characterization of a muscle-specific enhancer in human MuSK promoter reveals the essential role of myogenin in controlling activity-dependent gene regulation. *J Biol Chem.* 2006; 281:3943–3953. [PubMed: 16361705]
- Till JH, Becerra M, Watty A, Lu Y, Ma Y, Neubert TA, Burden SJ, Hubbard SR. Crystal structure of the MuSK tyrosine kinase: insights into receptor autoregulation. *Structure.* 2002; 10:1187–1196. [PubMed: 12220490]
- Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM, Davies K. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. *Nat Med.* 1998; 4:1441–1444. [PubMed: 9846586]
- Torres JC, Inestrosa NC. Heparin solubilizes asymmetric acetylcholinesterase from rat neuromuscular junction. *FEBS letters.* 1983; 154:265–268. [PubMed: 6832369]
- Trachtenberg JT, Thompson WJ. Schwann cell apoptosis at developing neuromuscular junctions is regulated by glial growth factor. *Nature.* 1996; 379:174–177. [PubMed: 8538769]
- Tsen G, Halfter W, Kroger S, Cole GJ. Agrin is a heparan sulfate proteoglycan. *J Biol Chem.* 1995; 270:3392–3399. [PubMed: 7852425]
- Tsim KW, Ruegg MA, Escher G, Kroger S, McMahan UJ. cDNA that encodes active agrin. *Neuron.* 1992; 8:677–689. [PubMed: 1314620]
- Ushkaryov YA, Petrenko AG, Geppert M, Sudhof TC. Neuexins: synaptic cell surface proteins related to the alpha-latrotoxin receptor and laminin. *Science.* 1992; 257:50–56. [PubMed: 1621094]

- Valdez G, Tapia JC, Kang H, Clemenson GD Jr, Gage FH, Lichtman JW, Sanes JR. Attenuation of age-related changes in mouse neuromuscular synapses by caloric restriction and exercise. *Proc Natl Acad Sci U S A*. 2010; 107:14863–14868. [PubMed: 20679195]
- van der Flier A, Gaspar AC, Thorsteinsdottir S, Baudoin C, Groeneveld E, Mummery CL, Sonnenberg A. Spatial and temporal expression of the beta1D integrin during mouse development. *Dev Dyn*. 1997; 210:472–486. [PubMed: 9415431]
- Voermans NC, Bonnemann CG, Huijing PA, Hamel BC, van Kuppevelt TH, de Haan A, Schalkwijk J, van Engelen BG, Jenniskens GJ. Clinical and molecular overlap between myopathies and inherited connective tissue diseases. *Neuromuscular disorders : NMD*. 2008; 18:843–856. [PubMed: 18818079]
- Voermans NC, Verrijp K, Eshuis L, Balemans MC, Egging D, Sterrenburg E, van Rooij IA, van der Laak JA, Schalkwijk J, S MvdM, Lammens M, van Engelen BG. Mild Muscular Features in Tenascin-X Knockout Mice, A Model of Ehlers-Danlos Syndrome. *Connective tissue research*. 2011
- Wallace BG, Nitkin RM, Reist NE, Fallon JR, Moayeri NN, McMahan UJ. Aggregates of acetylcholinesterase induced by acetylcholine receptor-aggregating factor. *Nature*. 1985; 315:574–577. [PubMed: 4010772]
- Wang J, Jing Z, Zhang L, Zhou G, Braun J, Yao Y, Wang ZZ. Regulation of acetylcholine receptor clustering by the tumor suppressor APC. *Nature neuroscience*. 2003; 6:1017–1018.
- Watty A, Burden SJ. MuSK glycosylation restrains MuSK activation and acetylcholine receptor clustering. *J Biol Chem*. 2002; 277:50457–50462. [PubMed: 12399462]
- Watty A, Neubauer G, Dreger M, Zimmer M, Wilm M, Burden SJ. The in vitro and in vivo phosphotyrosine map of activated MuSK. *Proc Natl Acad Sci U S A*. 2000; 97:4585–4590. [PubMed: 10781064]
- Weatherbee SD, Anderson KV, Niswander LA. LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. *Development*. 2006; 133:4993–5000. [PubMed: 17119023]
- Weston C, Gordon C, Teresa G, Hod E, Ren XD, Prives J. Cooperative regulation by Rac and Rho of agrin-induced acetylcholine receptor clustering in muscle cells. *J Biol Chem*. 2003; 278:6450–6455. [PubMed: 12473646]
- Williamson RA, Henry MD, Daniels KJ, Hrstka RF, Lee JC, Sunada Y, Ibraghimov-Beskrovnaya O, Campbell KP. Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in *Dag1*-null mice. *Hum Mol Genet*. 1997; 6:831–841. [PubMed: 9175728]
- Woldeyesus MT, Britsch S, Riethmacher D, Xu L, Sonnenberg-Riethmacher E, Abou-Rebyeh F, Harvey R, Caroni P, Birchmeier C. Peripheral nervous system defects in *erbB2* mutants following genetic rescue of heart development. *Genes Dev*. 1999; 13:2538–2548. [PubMed: 10521398]
- Wu H, Xiong WC, Mei L. To build a synapse: signaling pathways in neuromuscular junction assembly. *Development*. 2010; 137:1017–1033. [PubMed: 20215342]
- Xia B, Hoyte K, Kammesheidt A, Deerinck T, Ellisman M, Martin PT. Overexpression of the CT GalNAc transferase in skeletal muscle alters myofiber growth, neuromuscular structure, and laminin expression. *Dev Biol*. 2002; 242:58–73. [PubMed: 11795940]
- Xu R, Chandrasekharan K, Yoon JH, Camboni M, Martin PT. Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the *dyW* mouse model of congenital muscular dystrophy 1A. *Am J Pathol*. 2007; 171:181–199. [PubMed: 17591965]
- Xu R, DeVries S, Camboni M, Martin PT. Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice. *Am J Pathol*. 2009; 175:235–247. [PubMed: 19498002]
- Yang D, Bierman J, Tarumi YS, Zhong YP, Rangwala R, Proctor TM, Miyagoe-Suzuki Y, Takeda S, Miner JH, Sherman LS, Gold BG, Patton BL. Coordinate control of axon defasciculation and myelination by laminin-2 and -8. *J Cell Biol*. 2005; 168:655–666. [PubMed: 15699217]
- Yang X, Arber S, William C, Li L, Tanabe Y, Jessell TM, Birchmeier C, Burden SJ. Patterning of muscle acetylcholine receptor gene expression in the absence of motor innervation. *Neuron*. 2001; 30:399–410. [PubMed: 11395002]

- Yang X, Li W, Prescott ED, Burden SJ, Wang JC. DNA topoisomerase IIbeta and neural development. *Science*. 2000; 287:131–134. [PubMed: 10615047]
- Yoon JH, Chandrasekharan K, Xu R, Glass M, Singhal N, Martin PT. The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin. *Mol Cell Neurosci*. 2009; 41:448–463. [PubMed: 19442736]
- Yurchenco PD, Amenta PS, Patton BL. Basement membrane assembly, stability and activities observed through a developmental lens. *Matrix Biol*. 2004; 22:521–538. [PubMed: 14996432]
- Yurchenco PD, O'Rear JJ. Basal lamina assembly. *Curr Opin Cell Biol*. 1994; 6:674–681. [PubMed: 7833047]
- Yurchenco PD, Patton BL. Developmental and pathogenic mechanisms of basement membrane assembly. *Curr Pharm Des*. 2009; 15:1277–1294. [PubMed: 19355968]
- Zhang B, Luo S, Wang Q, Suzuki T, Xiong WC, Mei L. LRP4 serves as a coreceptor of agrin. *Neuron*. 2008; 60:285–297. [PubMed: 18957220]
- Zhao XT, Qian YK, Chan AW, Madhavan R, Peng HB. Regulation of ACh receptor clustering by the tyrosine phosphatase Shp2. *Dev Neurobiol*. 2007; 67:1789–1801. [PubMed: 17659592]
- Zhu D, Yang Z, Luo Z, Luo S, Xiong WC, Mei L. Muscle-specific receptor tyrosine kinase endocytosis in acetylcholine receptor clustering in response to agrin. *J Neurosci*. 2008; 28:1688–1696. [PubMed: 18272689]
- Zhu X, Lai C, Thomas S, Burden SJ. Neuregulin receptors, erbB3 and erbB4, are localized at neuromuscular synapses. *EMBO J*. 1995; 14:5842–5848. [PubMed: 8846777]
- Ziober BL, Vu MP, Waleh N, Crawford J, Lin CS, Kramer RH. Alternative extracellular and cytoplasmic domains of the integrin alpha 7 subunit are differentially expressed during development. *J Biol Chem*. 1993; 268:26773–26783. [PubMed: 8253814]



	E15		P0		P21	
	ESYN	SYN	ESYN	SYN	ESYN	SYN
<i>Ubiquitously Expressed</i>						
LN 211	+	+	+	+	+	+
Col IV ($\alpha 1$)₂($\alpha 2$)	+	+	+	+	+	+
Fibronectin	+	+	+	+	+	+
Nidogen 1	+	+	+	+	+	+
Perlecan	+	+	+	+	+	+
<i>Uniquely Synaptic</i>						
LN 221	-	+	-	+	-	+
LN 421	-	+	-	+	-	+
LN 521	-	+	-	+	-	+
Agrin (z8)	-	+	-	+	-	+
ColQ	-	+	-	+	-	+
AChE	-	+	-	+	-	+
Col IV ($\alpha 3$)($\alpha 4$)($\alpha 5$)	-	-	-	-	-	+
Col IV ($\alpha 5$)₂($\alpha 6$)	-	-	-	-	-	+
Col XIII	-	-	-	-	-	+
<i>Ubiquitous Then Synaptic</i>						
Agrin (z0)	+	+	+	+	-	+
Neuregulin	+	+	+	+	-	+
Nidogen 2	+	+	+	+	-	+
<i>Ubiquitous Then Extrasynaptic</i>						
LN 411	+	+	+	-	+	-
LN 511	+	+	+	-	+	-
<i>Other</i>						
LN 111	+	-	-	-	-	-

Figure 1. Developmental expression of synaptic extracellular matrix (ECM) proteins at the rodent neuromuscular junction

By embryonic (E) day 15, skeletal myofibers have formed and are innervated the nerve terminals of motor neurons at the neuromuscular junction. The nerve terminal is capped by a non-myelinating Schwann cell. Skeletal myofibers express a number of ECM proteins, including laminin (LN), collagen IV, fibronectin, perlecan, ColQ and nidogen, while motor nerves express ECM proteins including agrin (z8, 11, or 19) and neuregulin. Some ECM proteins are localized within the synaptic (SYN) basal lamina, which exists only at the neuromuscular junction, while other ECM proteins are present within the extrasynaptic (ESYN) basal lamina that surrounds the remainder of the skeletal myofiber membrane.

ESYN and SYN composition shifts during neuromuscular development as synaptic ultrastructure develops, such that unique laminin and collagen chains become expressed exclusively in the synaptic basal lamina in the postnatal (P) animal.




Figure 2. Synaptic extracellular matrix (ECM) proteins and their receptors at the neuromuscular junction

ECM proteins within the synaptic basal lamina at the neuromuscular junction include agrin, laminins, perlecan, collagen IVs, and ColQ. Potential ECM-receptor and ECM-ECM interactions are indicated in blue. Agrin contains splice sites in the N-terminus to allow for secreted and transmembrane forms and A/y and B/z splice sites in the C-terminus that allow heparin binding and AChR clustering, respectively. Laminins are heterotrimeric proteins comprised of an α , β , and γ chain. At the NMJ, the uniquely synaptic laminin chains are laminin β 2, laminin α 4, and laminin α 5. Collagen IVs are heterotrimeric proteins of

different three alpha chains. The NMJ contains two synaptic collagen IV trimers (($\alpha 3$, $\alpha 4$, $\alpha 5$) and ($\alpha 5$)₂($\alpha 6$)).

Legend: EGF, Epidermal growth factor-like repeat; FS, Follistatin-like domain; Ig, Immunoglobulin domain; LF, Laminin four domain (of the β chain); LB, Laminin B domain; L4, Laminin domain IV (of the γ or α chain); LE, Laminin EGF-like domain; LG, Laminin-like globular domain; LN, Laminin N-terminal domain; LA, LDL receptor domain class A; NtA, N-terminal agrin-laminin binding domain; PRAD, Proline-rich attachment domain; S/T, Serine/threonine-rich mucin-like domain; SP, Signal peptide; SEA, Sea urchin sperm protein, enterokinase, and agrin domain; TM, Transmembrane domain; AChE, Acetylcholinesterase; NCAM, Neural cell adhesion molecule; FGF, Fibroblast growth factor, HB-GAM, Heparin-binding growth-associated molecule; BMP, Bone morphogenetic protein; Lrp4, Low-density lipoprotein receptor-related protein 4; MuSK, Muscle-specific kinase; PDGF, Platelet-derived growth factor, LDL, Low density lipoprotein; HSPG, Heparan sulfate proteoglycan; VGCC, Voltage-gated calcium channel.




Figure 3. Synaptic ECM Signaling in Neuromuscular Development

Genetic evidence in mice and humans points to three central ECM-mediated groups of signals that are essential for proper neuromuscular development in muscle, those involving synaptic agrin, synaptic laminins and synaptic collagens. Signals from neuron-specific splice forms of agrin (for example z8) in the synaptic basal lamina (BL) work via the MuSK-LRP4 complex in the membrane to induce downstream tyrosine phosphorylation signals that drive synaptogenesis, which is agrin-independent, and to organize synaptic topography and induce synaptic stabilization, which are agrin-dependent. Down-stream signals are mediated or modulated by a variety of cytoplasmic effectors, including structural and adaptor/signaling proteins (Dok7, Dvl, Pak1, Tid1, APC, Rapsyn), proteases (Calpain), tyrosine kinases (Abl, Src, Fyn), tyrosine phosphatases (Shp2), serine/threonine kinases (Cdk5, CaMKII and CK2), small G proteins (Rho, Rac) and a geranylgeranyltransferase (GGT). Calcium entry stimulated by acetylcholine works, in part via Calpain, Cdk5 and CamKII to destabilize synaptic membranes. Laminins, particularly Laminin 421 and 521, in the synaptic BL signal via dystroglycan and possibly integrins in muscle to induce changes in synaptic ultrastructure and to maintain synaptic stability. Ultrastructural changes at the synapse are mediated, in part, by cytoplasmic dystroglycan-binding proteins including utrophin, syntrophins and dystrobrevins. These proteins help to link the ECM outside the muscle membrane to filamentous (F-) actin in the cytoskeleton. Laminin 421 and 521 also bind to the voltage-gated calcium channels in the presynaptic membrane to organize active zones. Collagens IV in the synaptic BL and collagen XIII in the postsynaptic membrane may signal via integrins to induce synaptic maturation and stability. Integrins may bind and signal through a variety of intracellular proteins (for example Focal adhesion kinase (FAK), vinculin, paxillin, talin).